<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC2017-2018_S08_ch15_p411-454</title>
		<link href="BCSC2017-2018_S08_ch15_p411-454-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC2017-2018_S08_ch15_p411-454" lang="en-US">
		<div id="_idContainer011" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter </span>15</p>
			<p class="chapter-title">Clinical Approach to Corneal Transplantation</p>
			<p class="video-list-mid ParaOverride-1"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;This chapter includes related videos, which can be accessed by scanning the QR codes provided in the text or going to www.aao.org/bcscvideo_section08.</p>
			<p class="h1">Highlights</p>
			<div id="Chapt15_Top1">
			<p class="body-text--no-indent-">
			<ul>
				<li class="bullet-list-mid">The trend toward selectively replacing pathologic corneal tissue has led to an increase in lamellar corneal surgery.</li>
				<li class="bullet-list-mid">Endothelial keratoplasty (EK) is now the procedure of choice for treating endothelial cell dysfunction. Advantages include preservation of structural integrity, faster visual recovery, and more predictable refractive outcomes.</li>
				<li class="bullet-list-mid">Deep anterior lamellar keratoplasty (DALK) preserves the host corneal endothelium, eliminating the risk of endothelial rejection and providing additional structural support in the case of trauma. However, DALK does not reduce postoperative astigmatism or prevent stromal rejection.</li>
			</ul>
			</p>
			</div>
			<p class="h1">Corneal Transplantation</p>
		<div id="Chapt15_Top2">
			<p class="body-text--no-indent-"><span class="italic">Corneal transplantation</span> refers to surgical replacement of a full-&#173;thickness host cornea (penetrating keratoplasty [PK]) or lamellar portion of the host cornea with that of a donor cornea. Ongoing innovations in lamellar transplantation have produced a virtual alphabet soup of nomenclature to describe the various approaches (<span class="xref-table">Table&#160;15-1</span>). If the donor is another person, the tissue is called an <span class="italic">allograft</span> and the procedure is referred to as <span class="italic">allogeneic </span><span class="italic">transplantation.</span> If the donor tissue is from the same or fellow eye, it is called an <span class="italic">autograft</span> and the procedure is referred to as <span class="italic">autologous transplantation</span> (see the section Corneal Autograft Procedures, later in the chapter).</p>
			<p class="body-text">A 2015 review by Park et al of corneal transplant procedures <span class="italic">(keratoplasty)</span> performed over the past 10&#160;years in the United States identified several trends. The number of transplants performed annually increased slightly from 2005 to 2014 (but peaked in 2008). However, there has been a dramatic shift in the types of procedures performed. The percentage of all transplants that were PK procedures decreased from 94.9% in 2005 to 41.5% in 2014. The percentage that were anterior lamellar keratoplasty (ALK) procedures (including DALK) increased slightly, but even by 2014, accounted for only 2.0% of total transplants. Most significantly, the percentage of all transplants that were EK procedures increased from 3.2% in 2005 to 55.9% in 2014; in the latter year, 49.7% were Descemet stripping endothelial keratoplasty (DSEK) and 6.2% were Descemet membrane endothelial keratoplasty (DMEK). The percentage that were keratoprosthesis procedures remained fairly stable at 0.6% of total transplants annually. </p>
			<p class="body-text">Table 15-2 lists the indications for transplantation of corneal tissue from US eye banks for procedures performed in the United States and internationally in 2016. The success of any transplant depends on the availability and quality of corneal tissue. The cornea surgeon is thus indebted to the Eye Bank Association of America and to the outstanding US and international eye banks that provide tissue.</p>
			<p class="reference-single--no-space- ParaOverride-2">Park CY, Lee JK, Gore PK, Lim CY, Chuck RS. Keratoplasty in the United States: a 10-year review from 2005 through 2014. <span class="italic">Ophthalmology.</span> 2015;122(12):2432–2442.</p>
			</div>
			<p class="h1">Keratoplasty and Eye Banking</p>
			<div id="Chapt15_Top3">
			<p class="h2-h1">Milestones in the History of Keratoplasty and Eye Banks</p>
			<p class="body-text--no-indent-">The first human corneal transplant, for a 45-year-old laborer with an opaque cornea due to a lime burn, was performed by Eduard Zirm in 1906. In 1919, Anton Elschnig performed a partial central corneal penetrating transplant. Vladimir Filatov, his student, was the first to use donor corneas from cadavers. In the 1930s, Ramon Castroviejo developed instruments specially designed for performing corneal transplantation. In 1944, R.&#160;Townley Paton established the first eye bank to provide a source of donated human eye tissue for keratoplasty.</p>
			<p class="body-text">In 1961, to establish uniform policies and procedures for corneal transplantation, 10&#160;eye banks formed the Eye Bank Association of America (EBAA). The 2017 EBAA membership currently includes all 69&#160;eye banks in the United States, as well as 13&#160;international eye banks.</p>
			<p class="h2">Modern Eye Banking and Donor Selection</p>
			<p class="body-text--no-indent-">The EBAA and the US&#160;Food and Drug Administration track all donor tissue, monitoring for infection to minimize the chance of transmission. Screening of the donor medical rec&#173;ord for potentially transmissible diseases is mandatory and is performed by an eye bank technician. Medical criteria that render a potential donor unsuitable for tissue recovery are listed in <span class="xref-table">Table&#160;15-3</span>, and diseases that can be transmitted from donor corneas are listed in <span class="xref-table">Table&#160;15-4</span>.</p>
			<p class="body-text">The eye bank technician also rigorously inspects the cadaver to rule out signs of high-risk behavior or other possible sources of potentially transmissible infectious diseases. Features like bluish-&#173;red cutaneous nodules (Kaposi sarcoma), needle marks, and recent tattoos can make the potential donor ineligible. If the cadaver passes inspection, blood samples are taken to rule out infectious diseases such as hepatitis&#160;B, hepatitis&#160;C, human immunodeficiency virus (HIV) infection, and syphilis.</p>
			<p class="body-text">Most eye banks accept corneal tissue from donors 2 to 75&#160;years of age, but eye donation at any age is to be encouraged. Donor tissue from a person younger than 2&#160;years is typically not used for transplant because it is extremely steep and flaccid, which makes the tissue difficult to handle and poses challenges in creating a watertight closure and achieving a predictable refractive outcome. The corneas of donors who have undergone cataract surgery are acceptable as long as they exceed the minimum acceptable cell count outlined in the eye bank’s policy (typically 2000&#160;cells/mm<span class="superscript CharOverride-1">2</span>). Corneas with lower endothelial cell counts and clear stroma may be suitable for anterior lamellar procedures. Conversely, corneas with anterior stromal opacities but high cell counts may be used for EK. Patients who have undergone keratorefractive surgery are not suitable donors for PK, but if all other parameters are satisfactory, their corneas may be used for EK. Responsibility for determining whether a donor cornea is suitable for transplantation ultimately rests with the transplant surgeon.</p>
			<p class="h2">Tissue Processing and Preservation</p>
			<p class="body-text--no-indent-">Originally, donor corneal tissue was preserved within the whole globe, which was refrigerated at 4°C in a glass jar that served as a moisture chamber; this allowed tissue to be used up to 24–48&#160;hours after donation. Extensive research on the importance of the endothelium for corneal allograft survival led to the development of McCarey-&#173;Kaufman (MK) medium, which extended the storage time to 4&#160;days. Optisol GS (Bausch&#160;+ Lomb, Bridgewater, NJ) is the most commonly used intermediate-&#173;term storage medium in the United States today, allowing the tissue to be stored for up to 7&#160;days after death and in some circumstances up to 14&#160;days. It contains chondroitin 2.5%, dextran 1%, ascorbic acid, and vitamin&#160;B<span class="subscript _idGenCharOverride-1">12</span>; it also includes gentamicin and streptomycin for broad-&#173;spectrum antibacterial coverage (<span class="xref-figure">Fig&#160;15-1</span>).</p>
			<p class="body-text">The process of tissue recovery includes slit-lamp evaluation and an endothelial cell count at the eye bank before release for transplantation. The optimal time from death to recovery is less than 12&#160;hours, but recovery is acceptable for up to 24&#160;hours postmortem. After recovery, the donor tissue is stored at 4°C until use. Many eye banks prepare tissue for Descemet stripping automated endothelial keratoplasty (DSAEK) and DMEK once a cornea is deemed suitable for EK.</p>
			<p class="body-text">Most eye banks in Europe incubate donor corneal tissue in organ culture storage at 37°C. Organ culture allows tissue to be stored for up to 35&#160;days but requires a culture at the end of the storage period to confirm sterility before the tissue is used. The organ culture system is more complex, costly, and labor-&#173;intensive than intermediate storage at 4°C, but the longer storage time is advantageous in places where the supply of donor corneas is limited.</p>
			<p class="body-text">Results of the Cornea Donor Study (CDS), a landmark study of eye bank–supplied corneal tissue, have greatly helped surgeons analyze and select donor tissue for their patients. The CDS, which completed enrollment in 2002 and conducted follow-&#173;up observations through 2012, evaluated the effect of donor age on graft survival in PK patients. Donors were grouped into cohorts age 10–64&#160;years and age 65–75&#160;years. At 5&#160;years, the study showed no difference in the rate of graft survival between the 2&#160;groups. However, at 10&#160;years the rate of graft survival was slightly higher in patients receiving tissue from donors in the younger group than those receiving tissue from donors in the older group.</p>
			<p class="reference-first">Eye Bank Association of America (EBAA). <span class="italic">2016 Eye Banking Statistical Report.</span> Washington, DC: EBAA; 2017.</p>
			<p class="reference-mid">Glasser DB. Medical standards for eye banking. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:287–297.</p>
			<p class="reference-mid">Lass JH, Beck RW, Benetz BA, et al; Cornea Donor Study Investigator Group. Baseline factors related to endothelial cell loss following penetrating keratoplasty. <span class="italic">Arch Ophthalmol.</span> 2011;<br />129(9):1149–1154.</p>
			<p class="reference-mid">Malling JV. Eye banking: structure and function. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:283–286.</p>
			<p class="reference-last--no-space-">Sugar A, Gal RL, Kollman C, et al; Writing Committee for the Cornea Donor Study Research Group. Factors associated with corneal graft survival in the Cornea Donor Study. <span class="italic">JAMA Ophthalmol.</span> 2015;133(3):246–254.</p>
			</div>
			<p class="h1 ParaOverride-3">Transplantation for the Treatment of Corneal Disease</p>
			<div id="Chapt15_Top4">
			<p class="body-text--no-indent-">Ophthalmologists have many options for surgically treating the wide spectrum of corneal disease. The procedure of choice depends primarily on the depth and extent of corneal pathology (<span class="xref-table">Table&#160;15-5</span>). Discussion of the surgical technique for these procedures is beyond the purview of this book; however, many excellent resources are available for this purpose and are listed in the references provided throughout the chapter. The following section discusses the preoperative evaluation of corneal transplant patients, and the rest of the chapter highlights the postoperative management of these patients in order to help the clinician make appropriate referrals and initiate treatment if necessary.</p>
			<p class="reference-first ParaOverride-2">Gorovoy MS. Advances in lamellar corneal surgery. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Academy of Ophthalmology; 2008, module&#160;4.</p>
			<p class="reference-mid">Hausheer JR, ed. <span class="italic">Basic Techniques of Ophthalmic Surgery.</span> 2nd&#160;ed. San Francisco: American Academy of Ophthalmology; 2015.</p>
			<p class="reference-last--no-space-">Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017.</p>
			<p class="h2">Preoperative Evaluation and Preparation of the Transplant Patient</p>
			<p class="body-text--no-indent-">A complete ophthalmic evaluation, including a history and examination, is necessary before corneal transplantation. The clinician should obtain a detailed social history to help determine whether the patient or caretakers can adhere to the potentially complex postoperative regimen. A history of amblyopia, macular degeneration, and glaucoma or other optic neuropathy will affect the visual prognosis and the decision to proceed with surgery.</p>
			<p class="body-text">The examination should include simple clinical tests, such as checking for color vision, light projection, and afferent pupillary defect, particularly in patients with media opacity. It is important to recognize that corneal and lens opacities can dramatically constrict visual fields. Overrefraction with a rigid contact lens can aid in determining the cause of decreased vision. Improvement in vision with the contact lens indicates that superficial irregular astigmatism is the cause; in such cases, the patient can be offered treatment with a contact lens. If vision does not improve, corneal opacification is the most likely cause of the reduced vision, necessitating surgical intervention. Optical coherence tomography (OCT) may help detect retinal problems such as macular edema (cystoid or diabetic) and age-&#173;related macular degeneration. If the media are completely opaque, standard B-scan ultrasonography is helpful in evaluating the posterior segment.</p>
			<p class="body-text">Prior to any corneal procedure but particularly before PK, DALK, or ALK, it is important to check for reduced corneal sensation. The loss of corneal sensation seen in herpes zoster or simplex disease may complicate the postoperative course because of prolonged epithelial healing. It is also important to diagnose and treat ocular surface problems such as dry eye, blepharitis, and rosacea, as well as eyelid problems such as trichiasis, lagophthalmos, entropion, and ectropion prior to corneal surgery. In older patients, the postoperative course may be more problematic; slower wound healing, decreased corneal sensation, and reduced or incomplete eyelid closure can lead to persistent epithelial defects, infections, and wound dehiscence. Deep corneal vascularization and a history of graft failure increase the risk of rejection in PK and DALK. The presence of an active keratitis or uveitis at the time of surgery is associated with a higher incidence of postoperative complications, such as graft rejection or failure, glaucoma, and cystoid macular edema. Ideally, there should be no ocular inflammation for several months prior to surgery. A history of glaucoma surgery, such as placement of filters or tube shunts, reduces endothelial cell survival and increases the risk of graft failure in EK and PK.</p>
			<p class="body-text">Fortunately, the advent of EK for endothelial dysfunction has minimized the impact of ocular surface disorders on the success of transplantation. The extent of stromal edema can be measured with corneal pachymetry, Scheimpflug imaging, or anterior segment OCT. (See Chapter&#160;2 for more discussion of these tests.) Typically, corneal edema is worse in the morning and improves throughout the day; this fluctuation can be documented through testing in the early morning and in the afternoon. In some patients, extensive guttae alone may cause enough reduction in vision or symptoms of glare to warrant surgery. For further discussion of the evaluation and indications for corneal surgery, see the references that follow.</p>
			<p class="reference-first">American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="italic">Corneal Edema and Opacification.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
			<p class="reference-mid">Hannush SB, Riveroll-&#173;Hannush L. Preoperative considerations and decision-&#173;making in keratoplasty. In: Mannis MJ, Holland EJ. eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:<br />1256–1263.</p>
			<p class="reference-last--no-space-">Watanabe S, Oie Y, Fujimoto H, et al. Relationship between corneal guttae and quality of vision in patients with mild Fuchs endothelial corneal dystrophy. <span class="italic">Ophthalmology.</span> 2015;<br />122(10):2103–2109.</p>
			</div>
			<p class="h1 ParaOverride-4">Penetrating Keratoplasty</p>
			<div id="Chapt15_Top5">
			<p class="body-text--no-indent-">The most common indications for PK are combined stromal and endothelial pathology, concomitant intraocular lens (IOL) suturing and anterior segment reconstruction, keratoconus, and, less frequently, endothelial dysfunction (<span class="xref-figure">Fig&#160;15-2</span>). Video&#160;15-1 shows PK performed to treat stromal scarring and endothelial decompensation due to congenital hereditary endothelial dystrophy. Video&#160;15-2 shows PK combined with scleral suture fixation of a posterior chamber IOL using an open-&#173;sky approach. To educate the patient about the risks and benefits of transplant surgery, the surgeon must understand potential intraoperative and postoperative complications, as well as postoperative management; these are discussed in the following subsections and summarized in <span class="xref-table">Table&#160;15-6</span>.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,/9j/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAlgAAAAEAAQCWAAAAAQAB/+4AJkFkb2JlAGQAAAAAAQMAEAMDBgkAAAAAAAAAAAAAAAAFAAJJRP/bAIQAAgICAgICAgICAgMCAgIDBAMDAwMEBQQEBAQEBQUFBQUFBQUFBQcICAgHBQkKCgoKCQwMDAwMDAwMDAwMDAwMDAEDAgIDAwMHBQUHDQsJCw0PDQ0NDQ8PDAwMDAwPDwwMDAwMDA8MDg4ODg4MERERERERERERERERERERERERERER/8IAEQgAPAA7AwERAAIRAQMRAf/EALsAAQEBAQADAQAAAAAAAAAAAAcIBgUAAgkDAQEAAAAAAAAAAAAAAAAAAAAAEAACAgIBAgYDAQAAAAAAAAAFBgQHAgMWEhdgERMUFRgAAScIEQABBAEDAgUCBQIDCQAAAAACAQMEBQYREhMUFQAhIhYHMSNBMkIzNDYXYiQ18FFhcVKDRGQ3EgEAAAAAAAAAAAAAAAAAAABgEwEAAgECBgIDAAAAAAAAAAABABEh8DEQYEGBobHR8WFx4f/aAAwDAQACEAMQAAAA5h2jmDAZIpkhgqAMTWhmReW0QAXWVoHYZmJAgehkMCDRR5+QvgCZI8OGfR0lUAgkLKB89BtDgWTCnaCgrA+d4qi8EgzhMbAnMWDdl6hqY0ZBDJgN+HBRx//aAAgBAgABBQHwB//aAAgBAwABBQHwB//aAAgBAQABBQGy7LJKZJxsporuFPsl8BWsYsjcL01vaxpPzHwzJbWSsQkPL+o08MzM7dloe+1D8BqhKCEILrEDAUlSEbmHAm/p+UJuD5E+3eHGWbDS0vRaUj2JqaAro2JUu0SygNckadOZBQRp2tm+dOK1x0sXFikCGQsNlTTY1giLf7MrszWrGogqPXDGKUirtwYPbq9PYOqt/imdnhvL3E0FR9kMwC3my18HLSi62hPZ9pshbbez4pZZJjVxypV4u2RX3ecEgN9e2dgnbF2bGaomoqw5Hk2vhdtC5KdIfN2iVzf/AD58DYhEuOJTJC2NgBK9fVdg26QmRxfLhZehuhsRdi83jErxSZ8aR7M8iy+vPs3jtJ0P3ZfiSh9auKW92U8j/wBZfS/j/wCf/9oACAECAgY/AQH/2gAIAQMCBj8BAf/aAAgBAQEGPwHIrGxyLMJKScwuqiFCqLpmujRo1czXuAm1yvmKuqzF/wB308SIcO7yLKLOPm1hUVhSpwEbkYqyoJWpABF1eJOtNWdu3Y5oSoem1YzU2fdxsYarKeDwXFq3XwYFpOpmXiS0lOxFAnEHlcUNAUnERfJPLxh0WP8AJvvS8q58SohyMVmNSytBkMuEcuyomikPvKyTAiojIDlU1VFD6eI1hkecL8n45lVtHgHYOygYHG4intZl2Qff4DkK4f2jIdOJfUWvljFnVfKlzlEKhk1MCTbY8+3PhWchZ5nKamV7AmTe1hxtDe51RAVFUPT54lAtMpzeTNzi0sA3196xEixGwvZta0IMnWyVVBBhF/Omv/Dx1/v7JOs7x7X5eqDdw+8uh6r9n+R0/wBvd9Nv6fGWY7QDm9bXz8zCHZS62yq+kCbPVplx9qNIqX3lEREVNEMtiaKajuTWBTUNvcyT+QckvtlhfTIW2yIKmIJrLY6SGbRGLfFHAlaIHdrh7wVAWkq5VTwWsOTriREPXRa+AlTL7y1Pcjq42boydzburjarJ0dbFGUVrxUHEx6VY0jT6Nzqdph5soOOqhckeZMJjYZ2ejL5uhtTVtdgghbUwWHc0Tk7J8eYx6qjtxnm2XIs+gkSXrtHCJCacBhuZHVxPq4hIjJKqFpi3XfHjg0FROjZNFJmPKB4kjTScflk4jjgtuvhHRtzeGiAAKgD+Yscq/j/ACHPJdFkDjs+RJal19fW1L8yS7JltI/YUiCXGRGuvL5r6UVS8dv7hk2vLydP3mq5eL3L3DvvJ0e3fp97XTbx/b03+rxmkn49rbKH8h4dMr6yKsuR2qrhybJ18JFuKMPr1W/gb5hcaXkFsR2uJ6UkZtlIzwxXGpbWSFWQ4zMa0e7mTVUskzr3E1ZachI4jhO9QqCaECALW61zPFvkZvCMIrJUtqqrIsmxZGXUNOusP2MtWI6yZD8p/a4pGJao4qmWq+KGdV4ILMJuixSqyBy1mI8xcRXKrVlhyuV59hAcFlSB1A5BFNC2qZCtnMg5dNxm7gVtxl9/fVs93s8N6waaFmHG4nEeVvWGXMYMciiobkL0okjHvkiRdZNQ5BjhnjcXE8gnHCJqKL7kmNJedlQHHnHkNEE5GqFqgb9o+nJcZ+P6t6PQfHDRt2uLPx4c2snIU9Jb7SyrI1ni60y8pEoggi4C8JloCr0/tSZ3f+2/dte8SeT277n6jtm/qP2u3/q15Nno/wAPjPHRtMiyCdfjkMKGHqV2mnY3GZkxyq4vUqEhwTs9YyqTStnqobVJV8Z1Y0rXsvFsajRiisDBbxyJeSpmrCRX50BXDlABkBAjgLvcNWiQRXerL8mVNxj5Rl0UHHLMqSQ45DxlhY7FiHNCIowRGnAgAjgNjohHtTci6reDmUPF37jBMVrL9mTRV0Z77DERsIzsJtxqKk2I4DurjL3G20vGAoYruG8x74qV1sq3CbmbV1Dr3U2E6bkUbglsGKkexyONe1qIkWvJ+Hh/5NtGar4/oq6rroLJMPOVzlgdFKlTmmWYzDDbQtTTk8BIhfgS7S10XLvk6MxFnzb6zrYPtGSQx7SWy/Ag18hGyaF1ZjW/ftju7W/Sjvkfl43dqt+h7PxdVuTfxd02+3OXm13dT9jpf29v2tdvl4sKiwmVZZd8eZDZVdFUPSwp3ZLdoMNuJLhznepTq4zsclREaXVVHyT8fjPJY+IZBHz2Y7bNyY9+w4wjoMwHtpnLIEGbIDcRqQC3vFG2kEV9a7MZprCA9RALglDRyIxDOzh9ZKcLUD6RyZyG4TRqSgbnHuP6r8bHez8rx9Z9Y6xVUNlLSnrY5VKx4saBYtvxnFUCbc+5K1FD27kbFC0GBm+GZGzQ2F5KODMt2GCjWrmUWqg2tXKiq8RRWUUG9EJSVrcRLu18TJGTwckqsKymrsWm6mniuIRxKiOrqvMWSiYEj5uGEkkZ0FtBX6eDmVfxNbuZJ8dVTjHHbRjmHFh3D5m6iShZYR5OlsSkK2gjq0umqa7vHU/3FL+j/wCb7ad5O0+5+n4Nncv4/wD43T667PXv/T4+Y3qzALa9h5vw4ZBmTH2wOI8iSAGWw30gF0es5F36rt2kquf9MPGcNuLLG7EYjrbL1pTTJsK+SLHfkusuaEyrshlFIuVkxE0VoEbRRVTpMzaCoZ+S8wspB1dTbg8DktibzyJ0qS31LRMmjO/i3Jow2XTuIbyo54yvGsWhRqPOIk9+trL+Q0c153DOVzo+zsbh5zbbGMjAhvJ0NTHXzXxCvYt+tRZwKN/GDxXH2xnxG8kfDSD0yDzOA8DhereRr+XTT8UxS6xyS3KvXKntlPZxnplEjBS3G336yJGSNKRE810WQ5yFqKfTTxcyHcInVd2xbDbR6+4bdq6pKRiiapZDsk5LY6BIBo22AU0UXTbTcaptLm/t6nZvYXc9n3f43feLtumuv+perf8AT8fy+MqtYGJWmbzpWbXtcat2F6DcSLDYrjYbRutmsAKKUk/qn/L6eMl+ObNMgaC8zidAo59c67OsqxYlXTzeGO9IWQ+PMRcev0RCJTVB1XxPmQgubu3YaWkljcS4BTGG7JhbJtamRPPpSNtlrglbSLzV1WvSiEnxnit9huNNTrCBAsL2azZz4TdZXVzTUes7fZuWDQvG1Hk6HwOubi9Xnpr4qbWHik6py2PZRLZqPVWsqwr3mLA9jVo87Mmy47EuKsciHqyAF1TkEhTysryg+OwOto5tLkOKWk6Q1VRR2yl5zkrOkxVFZCxkDpx2iGnILYq4pnaZPYtUPaItfEomUq5se7i2D1nYtTJguhNfnP74XVuPp5CKcKL5seS8PuHGOr7N02zt8Dpu3dx5u7bem15OD1bf4vP6tm3xlPH7y7r3V7vPYPdPTdw2hy69u+xu0266fhp4rf6k6n3BZdNx+5e7926KJ1uu3/Oa9Nxa6+Wmun6vHx97v9xadM17e2d+3fs+XPwefNxbt/N9zbu3eW7xH97+3vbXaz7bu4d3Q7G/9M4fuabdmnB/h0/Dxd+0Of2z2+3710vd/wCJwNdV136/29ODk89d/B6t/iL/AHP7723o42zj792zZuPh39H/AJbl11/N6/pr+Hij15el6I+k9r924NnSuc3P2j0c3S7uXk+5xfn9Hj8P/nH/ALf9If7f9zx//9oACAECAwE/EOQP/9oACAEDAwE/EOQP/9oACAEBAwE/EArdSxgwAKIAYVjbA6iHhFVXTCmqf9hAFxYHmqTKMszDrPkwVQrTbj61mqK3ViSE41adyaTqxFKs2+VtTEaSsKbfZS8v5GlAHSJmUGtMsiDDAAkTDeBCFPXa5+qC66ClIQYqy72K3EsZhBKxF4Uqb1wFYJ1lh+RaR+SNAk0VLFOhoRW4Dg/OBgOe02UHntIW/UwA9nPZus46X6TJopLtUtTZrDXHSZcyT70JVMtDPc1y1coCIBdyh22gpV6GjgEG0gHuatRj6S67/Cg1JyODmGsT3uiaG8pyRWdDNtDiFgblVtwxd5F/6vACuW1T9Jbx5V0FFSN61M2SPJ7U78yCGao2cNHqCYdukw6rTI/f0wCoxl242AZmgQI6cuuP3MokcAbdZolSnRkkgQbqYdfV7Flq0yzIgsY5DSeVWB+tZZJVlAqZCLcQD4nxKLbXj3Y+QI+NWXvWG/7yEpkkRXAZAQmmTfzWer23JWleCdbGi9a+WR6tUIaMEaXbiT20a1LIROD2dIwhsFQrGF+E8upC64guR9EQ7n+5SUukiRnYO8hWGGed6ikTCYcCEH3Ts2RRlWEUO+ezvDKIkErYipNtmMtHlfauTh1TYohEEFOOpoWIjm4w540US0qadp8DNY46/p0qbRCi5nHpHNaHiz5Tk72dRaL4+7IIGqys/gHoRorit51ob9evqf/Z" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-5"><span class="QR-code-number">Video 15-1</span> Penetrating keratoplasty for stromal scarring and endothelial dysfunction in congenital hereditary endothelial dystrophy.</p>
			<p class="QR-code-source-right">Courtesy of Robert W. Weisenthal, MD.</p>
			<p class="QR-code-text-right">Access all Section&#160;8 videos at www.aao.org/bcscvideo_section08.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-6"><span class="QR-code-number">Video 15-2</span> PK with scleral-&#173;sutured intraocular lens <br />using an open-&#173;sky approach.</p>
			<p class="QR-code-source-right ParaOverride-7">Courtesy of Robert W. Weisenthal, MD.</p>
			<p class="reference-single--no-space-">Chan CC, Perez MA, Verdier DD, Van Meter WS. Penetrating keratoplasty: the fundamentals. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1264–1276.</p>
			<p class="h2 ParaOverride-8">Intraoperative Complications</p>
			<p class="body-text--no-indent-">Complications that can occur during surgery are listed in Table&#160;15-6.</p>
			<p class="reference-single--no-space-">Chen MC, Mannis MJ. Intraoperative complications of penetrating keratoplasty. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1277–1282.</p>
			<p class="h2">Postoperative Care and Complications</p>
			<p class="body-text--no-indent-">The long-term success of a PK depends on appropriate postoperative management and conscientious patient adherence. Routine postsurgical care includes short-term use of topical antibiotics and a prolonged, perhaps indefinite, course of topical steroids (prednisolone, difluprednate ophthalmic emulsion 0.05%, fluorometholone 0.25% or 0.1%). (See “Prevention of graft rejection,” later in the chapter.) Frequent office visits are necessary to facilitate rapid vision rehabilitation and early recognition of the many complications that can occur after PK. The following sections review some common postsurgical complications.</p>
			<p class="reference-single--no-space- ParaOverride-9">Section&#160;3, Penetrating Keratoplasty: Postoperative Management. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1289–1354.</p>
			<p class="h3 ParaOverride-10">Primary donor failure (primary endothelial failure)</p>
			<p class="body-text--no-indent-">When a graft is edematous from the first postoperative day and remains so without inflammatory signs, a deficiency of donor endothelium should be suspected (<span class="xref-figure">Fig&#160;15-3</span>). Most surgeons allow at least 4&#160;weeks and up to 2&#160;months for spontaneous resolution of edema before considering regrafting. The cause of the donor failure is not always clear and may be related to intraoperative handling of the tissue.</p>
			<p class="h3 ParaOverride-10">Wound misalignment or leak</p>
			<p class="body-text--no-indent-">The wound is always checked carefully for aqueous leakage at the end of surgery. A Seidel test can be helpful in postoperatively assessing wound integrity, particularly in patients with low intraocular pressure (IOP) and a normal or shallow anterior chamber. Small wound leaks or suture track leaks without iris incarceration often close spontaneously. Patching, therapeutic contact lenses, and use of aqueous suppressants may facilitate a watertight seal. Resuturing is advised for leaks associated with shallow anterior chambers and low pressures lasting longer than 3&#160;days.</p>
			<p class="h3">Flat chamber or iris incarceration in the wound</p>
			<p class="body-text--no-indent-">If the IOP is low and there is a flat chamber or iris incarceration in the wound, the clinician should return the patient to surgery to reposit the iris, re-form the anterior chamber, and suture the wound. If the problem is not addressed promptly and appropriately, anterior synechiae may form, increasing the risk of graft rejection, glaucoma, or graft failure. Normal or high IOP with a shallow or flat anterior chamber may signify pupillary block or malignant glaucoma (aqueous misdirection). Initially, the surgeon should dilate the pupil to help break the pupillary block; if this is not successful, other measures are required. See BCSC Section&#160;10, <span class="italic">Glaucoma,</span> for discussion of pupillary block and malignant glaucoma.</p>
			<p class="h3 ParaOverride-11">Endophthalmitis</p>
			<p class="body-text--no-indent-">After PK, endophthalmitis may arise owing to intraoperative contamination, contamination of the donor corneal button, or postoperative invasion by microorganisms. The incidence of endophthalmitis is considerably higher in PK patients than cataract surgery patients, particularly if the vitreous is invaded or if the donor died of infection. Immunosuppressed patients with moderate to severe eyelid inflammation are also at greater risk for infection. Early recognition and aggressive intervention can save the eye and vision in some cases. Donor rim culture may identify any potential contaminants. See also BCSC Section&#160;9, <span class="italic">Intraocular Inflammation and Uveitis.</span></p>
			<p class="reference-single--no-space- ParaOverride-9">Chen JY, Jones MN, Srinivasan S, Neal TJ, Armitage WJ, Kaye SB; NHSBT Ocular Tissue Advisory Group and Contributing Ophthalmologists (OTAG Audit Study&#160;18). Endophthalmitis after penetrating keratoplasty. <span class="italic">Ophthalmology.</span> 2015;122(1):25–30.</p>
			<p class="h3 ParaOverride-11">Persistent epithelial defect</p>
			<p class="body-text--no-indent-">Large epithelial defects are common after PK, but they should heal within 7–14&#160;days. After this time, irreversible scarring and ulceration may occur. Patients who have reduced corneal sensation or decreased blink rate before surgery are at greater risk. Ocular surface disease (eg, dry eye, exposure, rosacea, blepharitis) should be identified and treated. Lubrication, patching, therapeutic contact lenses, punctal occlusion with plugs or cautery, and temporary or permanent lateral tarsorrhaphy may be helpful in difficult cases. (See the discussions of neurotrophic keratopathy and persistent epithelial defects in Chapter&#160;4 and of tarsorrhaphy in Chapter&#160;13.) If these measures are not successful, the diagnosis of herpetic keratitis (<span class="xref-figure">Fig&#160;15-4</span>) should be considered even if this was not the underlying reason for the graft. Oral antivirals can be used as a therapeutic trial.</p>
			<p class="h3 ParaOverride-11">Elevated intraocular pressure</p>
			<p class="body-text--no-indent-">High IOP may occur at any time after PK. Often, the first clinical sign is the loss of folds in the Descemet membrane. IOP elevation early in the postoperative period can be due to pupillary block, malignant glaucoma, hemorrhage or pigment blocking the trabecular meshwork, or an overly tight running suture. Elevated IOP starting a month or more after the procedure may be due to response to steroids such as topical prednisolone or difluprednate ophthalmic emulsion 0.05%. If glaucoma develops, aggressive treatment with appropriate topical medications, laser surgery, or other surgical intervention is indicated. Though uncommon, epithelial downgrowth or fibrous ingrowth can also cause postoperative pressure elevation. See also BCSC Section&#160;10, <span class="italic">Glaucoma.</span></p>
			<p class="h3">Recurrence of primary disease</p>
			<p class="body-text--no-indent-">Bacterial, fungal, viral, or amebic keratitis can recur in a graft in the early postoperative period. In recurrent infections, medical treatment directed at the causative agent is the initial form of therapy (see Chapters&#160;9 and&#160;10). Epithelial–stromal dystrophies such as granular or lattice dystrophy can superficially recur a year or later after the initial procedure (<span class="xref-figure">Fig&#160;15-5</span>). Visually significant lesions can be removed using phototherapeutic keratectomy (PTK); see Chapter&#160;13.</p>
			<p class="h3">Suture-related problems</p>
			<p class="body-text--no-indent-">Postoperative problems related to sutures include the following:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-12">excessive tightness of the sutures, producing an irregular astigmatism or elevated IOP</li>
				<li class="bullet-list-mid">loosening (usually as a result of wound contraction, suture breakage, resolution of wound edema, or suture cheese-&#173;wiring; <span class="xref-figure">Fig&#160;15-6</span>)</li>
				<li class="bullet-list-mid">breakage of a continuous suture</li>
				<li class="bullet-list-mid">infectious abscesses (usually localized around loose, broken, or exposed sutures; <span class="xref-figure">Fig&#160;15-7</span>)</li>
				<li class="bullet-list-mid">noninfectious (toxic) suture infiltrates, often multiple and in areas of pannus, or extension of sutures beyond the limbus</li>
				<li class="bullet-list-mid">giant papillary conjunctivitis from exposed knots</li>
				<li class="bullet-list-last ParaOverride-13">vascularization along suture tracks</li>
			</ul>
			<p class="body-text">Loose or broken sutures do not contribute to wound stability and should be removed as soon as possible. Loose sutures stain with fluorescein because they usually have broken through the corneal epithelium. Totally buried fragments of interrupted sutures may be left. Vascularization along the suture indicates that the wound is adequately healed in the vicinity and that sutures may be removed safely. Vascularized sutures are also prone to loosening and may increase the likelihood of graft rejection. After the sutures are removed, the refractive error or astigmatism may shift dramatically, so the surgeon should see the patient in 3–4&#160;weeks to ensure wound stability and to recheck refraction. The shift may occur even years after surgery.</p>
			<p class="h3 ParaOverride-11">Microbial keratitis</p>
			<p class="body-text--no-indent-">Long-term use of topical steroids, loss of corneal sensation after transplantation, uneven tear film, and suture exposure or erosion all predispose the patient to infectious keratitis, sometimes caused by unusual organisms. Culture of the infiltrate and the exposed suture is recommended, and initiation of broad-&#173;spectrum antibiotic therapy can help avoid graft failure. A peculiar form of keratitis, infectious crystalline keratopathy (<span class="xref-figure">Fig&#160;15-8</span>), is occasionally seen in grafts and other immunocompromised corneas. Branching colonies of organisms proliferate in the deep corneal stroma, with minimal or no inflammatory response. Many organisms have been implicated, but viridans streptococci are the most frequent causative organisms.</p>
			<p class="h3 ParaOverride-11">Late non–immune-mediated endothelial failure</p>
			<p class="body-text--no-indent-">In the absence of acute inflammation or graft rejection, visually significant corneal edema months to years after the procedure may be due to the normal loss of endothelial cells in tissue that had a marginal number of endothelial cells originally. The Cornea Donor Study showed that the 10-year cumulative probability of non–immune-&#173;mediated graft failure was higher in patients treated for pseudophakic or aphakic corneal edema than in patients treated for Fuchs endothelial corneal dystrophy. The higher failure rate may be related to the placement of a poorly designed anterior chamber lens or improper placement of the lens during previous, complex cataract surgery. Such problems may require an exchange of the IOL at the time of PK. In addition, patients with a prior diagnosis of glaucoma—especially those with a history of glaucoma surgery (particularly tube shunt implantation) and, to a lesser extent, those taking glaucoma medications—face a higher probability of graft failure than do patients who have no history of glaucoma.</p>
			<p class="reference-single--no-space- ParaOverride-14">Sugar A, Gal RL, Kollman C, et al; Writing Committee for the Cornea Donor Study Research Group. Factors associated with corneal graft survival in the Cornea Donor Study. <span class="italic">JAMA Ophthalmol.</span> 2015;133(3):246–254.</p>
			<p class="h3 ParaOverride-15">Graft rejection</p>
			<p class="body-text--no-indent-">Corneal allograft rejection rarely occurs within the first month; however, it may occur many years after PK. Fortunately, most episodes of graft rejection do not cause irreversible graft failure if recognized early and treated aggressively with steroids. Corneal transplant rejection after PK occurs in 4&#160;distinct clinical forms, which may occur either singly or in combination. (See BCSC Section&#160;9, <span class="italic">Intraocular Inflammation and Uveitis,</span> and Chapter&#160;11 in this volume for further discussion on the immunology of graft rejection.)</p>
			<p class="h4-text ParaOverride-15"><span class="h4-head">Epithelial rejection </span>The immune response may be directed entirely at the donor epithelium (<span class="xref-figure">Fig&#160;15-9</span>). Lymphocytes cause an elevated, linear epithelial ridge that advances centripetally. Because host cells replace lost donor epithelium, this form of rejection is problematic only in that it may herald the onset of endothelial rejection. Epithelial rejection occurs in a minority of patients experiencing rejection and is usually seen early in the postoperative period (1–13&#160;months). It may be asymptomatic; however, blurred vision may occur if the epithelial ridge is near the visual axis.</p>
			<p class="h4-text ParaOverride-15"><span class="h4-head">Subepithelial rejection </span>Corneal transplant rejection may also present as subepithelial infiltrates (<span class="xref-figure">Fig&#160;15-10</span>). These may be asymptomatic or may cause glare or reduced vision. It is not known whether these lymphocytic cells are directed at donor keratocytes or at donor epithelial cells. In atypical cases, a cellular anterior chamber reaction may accompany this form of rejection. Easily missed on cursory examination, subepithelial infiltrates can best be seen with broad, tangential illumination. They resemble the infiltrates associated with adenoviral keratoconjunctivitis. Subepithelial graft rejection may completely resolve if treated, but it may presage the more severe endothelial graft rejection.</p>
			<p class="h4-text ParaOverride-15"><span class="h4-head">Stromal rejection </span>Isolated stromal rejection is not common after PK; it is seen more commonly after DALK. It may present as stromal infiltrates, neovascularization, or, typically, noninfiltrative keratolysis within the graft–host interface that does not extend into the peripheral recipient stroma. In severe or prolonged episodes of graft rejection, the stroma can become necrotic.</p>
			<p class="h4-text ParaOverride-15"><span class="h4-head">Endothelial rejection </span>The most common and serious form of graft rejection is endothelial rejection, because loss of a significant number of endothelial cells leads to graft failure. Inflammatory precipitates are seen on the endothelial surface in fine precipitates, in random clumps, or in linear form underlying or in some cases outlining the area of corneal edema (Khodadoust line; <span class="xref-figure">Fig&#160;15-11</span>). Inflammatory cells are usually seen in the anterior chamber as well, but anterior uveitis is usually mild. As endothelial function is lost, the corneal stroma thickens with the development of posterior folds, and microcystic or bullous epithelial edema can occur. Patients have symptoms related to inflammation and corneal edema, such as photophobia, redness, irritation, halos around lights, or fogginess of vision.</p>
			<p class="h4-text ParaOverride-15"><span class="h4-head">Treatment </span>Frequent administration of steroid eyedrops is the mainstay of therapy for corneal allograft rejection. Either dexamethasone 0.1% or prednisolone 1% eyedrops are used, as often as every 15&#160;minutes to 2&#160;hours, depending on the severity of the episode. Difluprednate ophthalmic emulsion 0.05% can also be used, in less frequent doses; however, close follow-&#173;up to monitor for increased IOP is recommended. Although topical steroid ointment may be used on occasion, the reduced bioavailability of topical ointment is not as effective as frequently applied eyedrops.</p>
			<p class="body-text">Steroids may be given by periocular injection (triamcinolone acetonide 0.5&#160;cc of 40&#160;mg/mL or dexamethasone 0.5&#160;cc of 4&#160;mg/mL) for severe rejection episodes or nonadherent patients. Caution is advised in patients who may have steroid-&#173;induced elevation of IOP or a history of herpetic keratitis. In particularly fulminant cases, steroids may be administered either orally (80&#160;mg per day, tapered as the graft rejection responds) or intravenously (a one-time dose of 125–500&#160;mg methylprednisolone).</p>
			<p class="h4-text ParaOverride-9"><span class="h4-head">Prevention of graft rejection</span> Surgical techniques that avoid proximity to the peripheral cornea and early attention to loosening sutures and infections will minimize the risk of rejection.</p>
			<p class="body-text">According to a survey of members of the Cornea Society conducted in 2011, prednisolone is the topical steroid of choice for prophylaxis against graft rejection; however, some surgeons prefer dexamethasone instead. In low-risk cases, the dosage is typically 4&#160;times per day for at least 3&#160;months; it is then tapered by 1&#160;drop either each month or every 2&#160;months until it has been reduced to once per day. Notably, 13% of respondents reported using difluprednate in high-risk eyes for the first 6&#160;months. In patients with a steroid response causing ocular hypertension, respondents reported substituting loteprednol etabonate ophthalmic suspension or fluorometholone. The phakic patient may be tapered off steroids or maintained on one of low-&#173;concentration to minimize the risk of cataract. The pseudophakic patient is typically kept on a once-&#173;daily steroid regimen. Patients using steroids should continue to be followed for IOP elevation, which can occur many months or even years after treatment.</p>
			<p class="body-text">Long-term immunosuppressive agents such as topical cyclosporine have been used to prevent graft rejection, but in general, cyclosporine is not as effective as topical steroids. In high-risk cases, the use of various immunosuppressive agents, including oral cyclospor&#173;ine, tacrolimus, and mycophenolate mofetil, has been reported, but these medications require very careful follow-&#173;up because of their narrow therapeutic index. Topical tacrolimus has also been advocated for use in high-risk patients.</p>
			<p class="reference-single--no-space-">Kharod-Dholakia B, Randleman JB, Bromley JG, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns of the Cornea Society (2011). <span class="italic">Cornea.</span> 2015;<br />34(6):609–614.</p>
			<p class="h2">Control of Postoperative Corneal Astigmatism and Refractive Error</p>
			<p class="body-text--no-indent-">A corneal transplant was once considered successful merely if the graft remained clear. Today, success is also measured based on the refractive outcome. Severe astigmatism may be associated with decreased visual acuity, anisometropia, aniseikonia, image distortion, and monocular diplopia, rendering an otherwise clear graft poorly functional. Many methods have been suggested to reduce astigmatism, including</p>
			<ul>
				<li class="bullet-list-first">variation of suture techniques</li>
				<li class="bullet-list-mid">intraoperative adjustments with qualitative keratometry</li>
				<li class="bullet-list-mid">improvement of trephines and use of new technology, such as the femtosecond laser (femtosecond laser–assisted keratoplasty [FLAK]), to better match donor and host tissue (however, the efficacy of matching the tissue with the femtosecond laser has not been shown to reduce astigmatism in long-term clinical studies)</li>
				<li class="bullet-list-mid">selective suture removal or adjustment of the continuous suture using corneal topography and tomography for postoperative management</li>
				<li class="bullet-list-mid">incisional or ablative refractive surgery</li>
				<li class="bullet-list-last">secondary intraocular procedures after the graft has stabilized</li>
			</ul>
			<p class="body-text">The primary method of reducing astigmatism postoperatively is to readjust or remove the sutures. However, before suture removal or adjustment is considered, it is essential to ensure that a smooth and regular epithelium is present. Careful attention to the ocular surface and appropriate management of topical therapy expedite reaching this point. If a single continuous suture technique has been used, the surgeon may redistribute the suture tension at 1&#160;month postoperatively, using corneal topography as a guide. Alternatively, if there is a combination of continuous and interrupted sutures, the interrupted sutures can be removed starting at 1&#160;month. If the patient has only interrupted sutures, suture removal should begin at a later stage to avoid wound slippage or dehiscence. Clinicians must be especially careful with older patients placed on long-term topical steroid therapy, as wound healing is often slower in these patients.</p>
			<p class="body-text">Prior to removal of the sutures, the most critical step is to identify the steep axis using corneal topography, photokeratoscopy, or manual keratometry. For example, in <span class="xref-figure">Figure&#160;15-12</span> the simulated keratometry readings from the topographer show a steep axis of 49.93&#160;diopters&#160;(D) at 11 and a flat axis of 44.06&#160;D at 101. The photokeratoscopic image shows clear rings that are oval in contour, with the shorter axis horizontally corresponding to the steep axis. The presence of distinct rings demonstrates the smooth surface indicative of regular astigmatism. Rings that are very irregular or indistinct may indicate irregular astigmatism; in such cases, suture removal is not recommended until clear and stable measurements can be obtained. Surface disruption may distort keratoscopic mires, but a drop of a tear supplement can temporarily make the mires more distinct.</p>
			<p class="body-text">Manifest refraction can aid in confirming the steep axis (plus cylinder). The autorefraction in Figure&#160;15-12 is –9.00 +6.75 at 4°. The manifest refraction is –7.00 +5.00 at 4°, resulting in 20/25 acuity; the good visual acuity confirms the presence of regular astigmatism. Removing the interrupted sutures on one or both sides of the 4° meridian or adjusting the continuous suture will compensate for the induced astigmatism. After manipulation or removal of the sutures, the patient uses a topical antibiotic for 4&#160;days and returns for a follow-&#173;up visit in 1&#160;month for corneal topography and manifest refraction.</p>
			<p class="body-text">If the patient has intolerable anisometropia or significant astigmatism after adjustment or removal of selected sutures, a contact lens can be tried. After removal of all sutures, relaxing incisions—performed with a metal or diamond knife or a femtosecond laser—are effective in treating residual regular astigmatism. The arcuate incisions are placed either in the donor cornea anterior to the graft–host junction or in the graft–host interface at the steep (plus cylinder) meridian. Suture placement at the flat meridian can augment the effect. Laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) have also been used to manage residual anisometropia and astigmatism after transplantation (see BCSC Section&#160;13, <span class="italic">Refractive Surgery</span>).</p>
			<p class="body-text">If the patient has a visually significant cataract associated with anisometropia following PK, cataract extraction with appropriate IOL power selection will reduce anisometropia. If the patient has visually significant regular, stable astigmatism with a healthy graft endothelium, a toric IOL is also an option. If the patient has intolerable anisometropia with a clear lens, the surgeon may elect to place a phakic IOL or perform a refractive lens exchange.</p>
			<p class="body-text">Risks of surgical intervention include microperforation and macroperforation, infection, rejection, undercorrection or overcorrection, persistent epithelial defects, and production of irregular astigmatism. Any intraocular procedure following corneal transplantation has the potential to damage the endothelial cells and can lead to graft failure.</p>
				</div>
			<p class="h1">Lamellar Keratoplasty</p>
			<div id="Chapt15_Top6">
			<p class="body-text--no-indent-">With advances in surgical instruments and techniques, cornea surgeons are now able to selectively remove diseased or scarred corneal tissue while preserving healthy tissue. Removal and replacement of select layers of the cornea is called lamellar keratoplasty. The general ophthalmologist should be familiar with the indications and limitations of, and common complications associated with, the various types of lamellar keratoplasty, including ALK, DALK, DSEK, and DMEK (see Table&#160;15-6). DSEK and DMEK are discussed separately later in this chapter.</p>
			<p class="h2 ParaOverride-8">Anterior Lamellar Keratoplasty</p>
			<p class="body-text--no-indent-">Anterior lamellar keratoplasty is an excellent option for patients with opacities or loss of tissue not involving the full thickness of the cornea. These conditions include corneal thinning (eg, Terrien marginal degeneration, descemetocele formation, pellucid marginal degeneration, keratoconus; <span class="xref-figure">Fig&#160;15-13</span>), superficial corneal tumors, and peripheral ulcerative keratitis with significant keratolysis. See Table&#160;15-6 for additional information.</p>
			<p class="h3 ParaOverride-10">Advantages</p>
			<p class="body-text--no-indent-">Anterior lamellar keratoplasty has many advantages over PK. It eliminates a full-&#173;thickness corneal incision into the anterior chamber, thereby avoiding the risks of glaucoma, cataract, retinal detachment, cystoid macular edema, expulsive hemorrhage, and endophthalmitis. Because the endothelium is not transplanted, it also eliminates the risk of endothelial rejection and, consequently, decreases the need for topical steroids.</p>
			<p class="h3 ParaOverride-10">Disadvantages</p>
			<p class="body-text--no-indent-">Anterior lamellar keratoplasty does not replace damaged endothelium. Also, the procedure is more technically demanding and time-&#173;consuming than PK. It may be associated with irregular or significant regular astigmatism, opacification and vascularization of the graft–host interface, and stromal rejection is still possible and may be problematic.</p>
			<p class="reference-first">Fontana L, Iovieno A. Techniques of anterior lamellar keratoplasty. In: Mannis MJ, Holland&#160;EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1361–1365.</p>
			<p class="reference-mid">Gorovoy MS. Advances in lamellar corneal surgery. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Academy of Ophthalmology; 2008, module&#160;4.</p>
			<p class="reference-last--no-space-">John T, ed. <span class="italic">Surgical Techniques in Anterior and Posterior Lamellar Corneal Surgery.</span> New Delhi, India: Jaypee Brothers Medical Publishers; 2006.</p>
			<p class="h3 ParaOverride-10">Deep anterior lamellar keratoplasty</p>
			<p class="body-text--no-indent-">In contrast to ALK, in which the excision of tissue may extend only to the pathology found in the superficial or midstromal tissue, the goal of DALK is to remove the entire stromal layer. DALK has become more popular for the treatment of keratoconus, corneal dystrophies, and corneal scarring. (See Videos&#160;15-3 and 15-4, which demonstrate DALK procedures.) To obtain a visual outcome similar to that achieved with PK, the surgeon must dissect down to or close to the Descemet membrane to create a clear, smooth graft–host interface. There are many techniques for dissecting stromal tissue to expose the Descemet membrane, including the Anwar big-&#173;bubble technique (see Videos&#160;15-5 and 15-6 for animations of the big-&#173;bubble technique), the Melles technique, and, more recently, the use of the femtosecond laser. As discussion of these techniques is beyond the purview of this chapter, the reader is encouraged to consult the references that follow. Even in experienced hands, it may not always be possible to expose the Descemet membrane using these techniques. In these cases, manual dissection is possible, but it poses a risk of reduced best-&#173;corrected visual acuity due to incomplete removal of the host stromal tissue and secondary interface haze. In an OCT study of patients who underwent DALK, 20&#160;µm of residual stromal bed was not visually significant; however, 80&#160;µm of residual tissue caused a reduction in vision.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-16"><span class="QR-code-number">Video 15-3</span> Deep anterior lamellar keratoplasty for keratoconus.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Robert W. Weisenthal, MD.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-16"><span class="QR-code-number">Video 15-4</span> DALK.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of David D. Verdier, MD. Deep anterior lamellar keratoplasty. In: <span class="CharOverride-2">Copeland and Afshari’s Principles and Practice of Cornea.</span> New Delhi, India: Jaypee Brothers Medical Publishers; 2013.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-18"><span class="QR-code-number">Video 15-5</span> Formation of the big bubble in DALK.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Dasa Gangadhar, MD.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-16"><span class="QR-code-number">Video 15-6</span> Decompression of the big bubble in DALK.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Dasa Gangadhar, MD.</p>
			<p class="reference-first ParaOverride-2">Anwar M, Teichmann KD. Big-&#173;bubble technique to bare Descemet’s membrane in anterior lamellar keratoplasty. <span class="italic">J&#160;Cataract Refract Surg.</span> 2002;28(3):398–403.</p>
			<p class="reference-mid">Ardjomand N, Hau S, McAlister JC, et al. Quality of vision and graft thickness in deep <br />anterior lamellar and penetrating corneal allografts. <span class="italic">Am&#160;J Ophthalmol.</span> 2007;143(2):<br />228–235.</p>
			<p class="reference-mid">Chen G, Tzekov R, Wensheng L, Jiang F, Mao S, Tong Y. Deep anterior lamellar keratoplasty versus penetrating keratoplasty: a meta-&#173;analysis of randomized controlled trials. <span class="italic">Cornea.</span> 2016;35(2):169–174.</p>
			<p class="reference-last--no-space-">Reinhart WJ, Musch DC, Jacobs DS, Lee WB, Kaufman SC, Shtein RM. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty: a report by the American Academy of Ophthalmology. <span class="italic">Ophthalmology.</span> 2011;118(1):209–218.</p>
			<p class="h2 ParaOverride-19">Complications</p>
			<p class="h3-h2">Complications associated with lamellar keratoplasty</p>
			<p class="h4-text-h3"><span class="h4-head">Opacification and vascularization of the interface</span> Meticulous dissection of the lamellar plane during both ALK and DALK is essential to creation of a smooth, clear interface. Irrigation and cleaning of the lamellar bed at the time of surgery reduces the likelihood of postoperative opacification. Retained interface debris, secondary vascularization, microbial infections, or wrinkling of the Descemet membrane can reduce vision or prolong vision rehabilitation. Neovascularization can increase the risk of lipid keratopathy, leading to further corneal opacification.</p>
			<p class="h4-text ParaOverride-2"><span class="h4-head">Allograft rejection</span> Because the corneal endothelium is not transplanted, endothelial rejection cannot take place. Epithelial rejection, subepithelial infiltrates, and stromal rejection can still occur, but they usually respond to corticosteroid therapy. Stromal rejection, characterized by significant haze and deep vascularization, can lead to corneal opacification and is more common after DALK than PK (<span class="xref-figure">Fig&#160;15-14</span>).</p>
			<p class="h3">Complications unique to deep anterior lamellar keratoplasty</p>
			<p class="h4-text-h3"><span class="h4-head">Rupture of the Descemet membrane</span> If there is a small rupture, the procedure may still be completed but may result in a Descemet detachment (see the following discussion). If there is a large perforation, conversion to PK may be necessary.</p>
			<p class="h4-text ParaOverride-2"><span class="h4-head">Double anterior chamber or Descemet detachment</span> Descemet detachment or pseudo–double anterior chambers can occur because of fluid in the interface, which results from a host perforation or retained viscoelastic material. Injection of air into the anterior chamber can help with reattachment; however, it may also reduce the endothelial cell count and lead to the development of an anterior subcapsular cataract.</p>
			<p class="h3">Postoperative complications common to lamellar and penetrating keratoplasty</p>
			<p class="body-text--no-indent-">Complications common to lamellar and penetrating keratoplasty include prolonged healing due to ocular surface disease, suture erosion and abscess, infectious keratitis, neovascularization, graft rejection, and graft failure.</p>
			</div>
			<p class="h1 ParaOverride-20">Endothelial Keratoplasty</p>
			<div id="Chapt15_Top7">
			<p class="body-text--no-indent-">In 1998, Gerrit Melles introduced the concept of lamellar surgery for endothelial dysfunction through a procedure called deep lamellar endothelial keratoplasty (DLEK). Because the manual dissection (of the host and donor corneal tissue) in DLEK was technically challenging, this technique was not widely adopted by cornea surgeons. Melles modified the technique to include stripping of the host Descemet membrane and endothelium (descemetorrhexis) and insertion of a hand-&#173;dissected posterior lamellar donor button, which was positioned against the host with an air bubble in the anterior chamber; the revised technique was coined Descemet stripping endothelial keratoplasty (DSEK). Mark Gorovoy later automated the lamellar dissection of the donor tissue by using a microkeratome, giving rise to the procedure he called Descemet stripping automated endothelial keratoplasty (DSAEK). Over time, the term DSEK has been adopted for these automated procedures as well; in this book, the term DSEK is similarly used.</p>
			<p class="body-text">Melles further modified the DSEK procedure by using only donor Descemet membrane and endothelium in a procedure termed Descemet membrane endothelial keratoplasty (DMEK). Further innovations to the technique used to insert and unscroll the tissue, the adoption of an “S”&#160;stamp for graft orientation, and the use of SF<span class="subscript _idGenCharOverride-1">6</span> gas to extend the duration of the gas bubble have significantly reduced the incidence of postoperative complications and increased the use and success of DMEK. In addition, the availability of eye bank–prepared tissue for DSEK and DMEK has increased the safety and popularity of both procedures.</p>
			<p class="body-text">EK is now the preferred technique for treatment of patients with corneal endothelial dysfunction, and it has been adopted for use in pediatric patients with congenital or early corneal edema (see the discussion of pediatric keratoplasty later in the chapter). Due to the success of, and rapid rehabilitation observed with, EK, the indications for this procedure have expanded to include patients with visually significant cornea guttae in the absence of stromal edema. <span class="xref-table">Table&#160;15-7</span> shows the increased use of DSEK and DMEK in the United States since 2013. Comparisons of PK and endothelial surgery are provided in Tables&#160;15-6 and <span class="xref-table">15-8</span>. Videos&#160;15-7 through 15-10 show the DSEK and DMEK procedures.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer007" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"><span class="QR-code-number">Video 15-7</span> Descemet stripping endothelial keratoplasty.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Robert W. Weisenthal, MD.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"><span class="QR-code-number">Video 15-8</span> DSEK combined with phacoemulsification and IOL implantation.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Robert W. Weisenthal, MD.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"><span class="QR-code-number">Video 15-9</span> Descemet membrane endothelial keratoplasty.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Robert W. Weisenthal, MD.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer010" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"><span class="QR-code-number">Video 15-10</span> DMEK combined with phacoemulsification and IOL implantation.</p>
			<p class="QR-code-source ParaOverride-17">Courtesy of Robert W. Weisenthal, MD.</p>
			<p class="reference-first">Lee WB, Jacobs DS, Musch DC, Kaufman SC, Reinhart WJ, Shtein RM. Descemet’s stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. <span class="italic">Ophthalmology.</span> 2009;116 (9):1818–1830.</p>
			<p class="reference-mid">Section&#160;6, Endothelial Keratoplasty. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1427–1508.</p>
			<p class="reference-mid">Terry MA, Straiko MD, Veldman PB, et al. Standardized DMEK technique: reducing complications using prestripped tissue, novel glass injector, and sulfur hexafluoride (SF6) gas. <span class="italic">Cornea.</span> 2015;34(8):845–852.</p>
			<p class="reference-last--no-space-">Waggoner M, Cohen AW. Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK). In: <span class="italic">Basic Techniques of Ophthalmic Surgery.</span> 2nd&#160;ed. San Francisco: American Academy of Ophthalmology; 2015:<br />145–152.</p>
			<p class="h2 ParaOverride-21">Advantages</p>
			<p class="body-text--no-indent-">Because the donor tissue is inserted through a small corneal or scleral incision in EK procedures (compared with the large full-&#173;thickness central corneal incision used in other keratoplasty procedures), the structural integrity of the eye is preserved, and any subsequent trauma to the eye will result in less damage (<span class="xref-figure">Fig&#160;15-15</span>). Other advantages include reduced incidence of graft rejection, reduction in suture-&#173;related problems, less induced astigmatism with greater accuracy in IOL power calculations, and more rapid vision rehabilitation (due to preservation of the ocular surface and the rapid return of endothelial function).</p>
			<p class="h2 ParaOverride-21">Disadvantages</p>
			<p class="body-text--no-indent-">The main disadvantages of EK include the potential for wasting donor tissue (due to poor harvesting, which is minimized with eye bank–prepared tissue), increased risk of primary graft failure during surgical learning curve, and the need for additional surgical interventions postoperatively (re-&#173;injection of air, or <span class="italic">rebubbling</span>). Reduced postoperative visual acuity is another potential drawback and is discussed separately in the following subsection.</p>
			<p class="h3 ParaOverride-10">Potential for reduced postoperative visual acuity</p>
			<p class="body-text--no-indent-">Coexisting corneal pathology such as basement membrane changes or subepithelial fibrosis may cause surface irregularity that limits vision after DSEK or DMEK. In some cases, debridement or superficial keratectomy may be necessary. Another possible cause of decreased vision after EK is light scattering due to preexisting long-&#173;standing corneal edema. An evaluation of patients with Fuchs corneal dystrophy who underwent DSEK revealed that the corneal light scattering associated with anterior stromal haze improved significantly after surgery but was still increased compared with that in a normal cornea 24&#160;months after the procedure.</p>
			<p class="body-text">A review of the literature on DSEK outcomes found that the average best-&#173;corrected Snellen visual acuity (BCSVA) ranged from 20/34 to 20/66. Also, an American Academy of Ophthalmology (AAO) <span class="italic">Preferred Practice Pattern</span> guideline reported that in a review of studies, a best spectacle-&#173;corrected visual acuity of 20/40 or better was achieved at 1&#160;year in 38%–90% of patients after DSEK compared with 97% of patients after DMEK; further, 39%–47% of patients had 20/20 vision after DMEK (see Table&#160;15-8). A number of studies have compared DMEK and DSEK, and all concluded that DMEK provided more rapid recovery of visual acuity and a better final visual outcome. The difference in visual outcome between DSEK and DMEK may be related to the alteration of the posterior corneal curvature that occurs with DSEK. This alteration is due to the unevenness and thickness of the donor tissue and the irregularity of the interface between the donor stromal tissue and the host Descemet membrane. This is in contrast to the nearly normal anatomical restoration of the cornea achieved with DMEK, which is due to the extremely thin graft tissue used and the exceedingly smooth interface created between the host Descemet membrane and transplanted Descemet membrane and endothelium in DMEK.</p>
			<p class="body-text">Nevertheless, for many surgeons, DSEK is still the procedure of choice for routine EK, because manipulation and placement of tissue are easier with this technique. DSEK is particularly useful in patients with disorganized anterior segments, those with sutured posterior chamber or anterior chamber IOLs, and in patients who have undergone tube shunt implantation or other glaucoma procedures. In an effort to improve the visual outcome after DSEK, some surgeons advocate using thinner donor grafts (between 90 and 120&#160;µm), a variation called <span class="italic">ultrathin DSEK.</span> However, Wacker et al, in a meta-&#173;analysis of 23&#160;series, found that there may be a weak correlation but overall insufficient evidence to conclude that graft thickness is clinically important with respect to BCVA after DSEK. These same investigators have also shown that visual acuity after DSEK continues to improve over a 5-year period, with more than half of the patients seeing better than 20/25 at 5&#160;years, which they believe was a result of ongoing remodeling of the cornea reducing corneal haze and aberrations.</p>
			<p class="reference-first">American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="italic">Corneal Edema and Opacification.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
			<p class="reference-mid">Baratz KH, McLaren JW, Maguire LJ, Patel SV. Corneal haze determined by confocal microscopy 2&#160;years after Descemet stripping with endothelial keratoplasty for Fuchs corneal dystrophy. <span class="italic">Arch Ophthalmol.</span> 2012;130(7):868–874.</p>
			<p class="reference-mid">Dickman MM, Kruit PJ, Remeijer L, et al. A randomized multicenter clinical trial of ultrathin Descemet stripping automated endothelial keratoplasty (DSAEK) versus DSAEK. <span class="italic">Ophthalmology.</span> 2016;123(11):2276–2284.</p>
			<p class="reference-mid">Hamzaoglu EC, Straiko MD, Mayko ZM, Sáles CS, Terry MA. The first 100&#160;eyes of standardized Descemet stripping automated endothelial keratoplasty versus standardized Descemet membrane endothelial keratoplasty. <span class="italic">Ophthalmology.</span> 2015;122(11):2193–2199.</p>
			<p class="reference-mid">Roberts HW, Mukherjee A, Aichner H, Rajan MS. Visual outcomes and graft thickness in microthin DSAEK—one year results. <span class="italic">Cornea.</span> 2015;34(11):1345–1350.</p>
			<p class="reference-mid">Rudolph M, Laaser K, Bachmann BO, Cursiefen C, Epstein D, Kruse FE. Corneal higher-&#173;order aberrations after Descemet’s membrane endothelial keratoplasty. <span class="italic">Ophthalmology.</span> 2012;<br />119(3):528–539.</p>
			<p class="reference-mid">Tourtas T, Laaser K, Bachmann BO, Cursiefen C, Kruse FE. Descemet membrane endothelial keratoplasty versus Descemet stripping automated endothelial keratoplasty. <span class="italic">Am&#160;J Ophthalmol.</span> 2012;153(6):1082–1090.</p>
			<p class="reference-mid">Wacker K, Baratz KH, Maguire LJ, McLaren JW, Patel SV. Descemet stripping endothelial keratoplasty for Fuchs’ corneal endothelial dystrophy: five-year results of a prospective study. <span class="italic">Ophthalmology.</span> 2016;123(1):154–160.</p>
			<p class="reference-last--no-space-">Wacker K, Bourne WM, Patel SV. Effect of graft thickness on visual acuity after Descemet stripping endothelial keratoplasty: a systematic review and meta-&#173;analysis. <span class="italic">Am&#160;J Ophthalmol.</span> 2016;163:18–28.</p>
			<p class="h2">Intraoperative Complications</p>
			<p class="body-text--no-indent-">Complications that can occur during DSEK or DMEK include improper orientation during placement of the donor tissue; excessive manipulation of the donor tissue, leading to cell loss and possible graft failure; tearing of the donor tissue; retention of viscoelastic; and vitreous or blood in the interface (<span class="xref-figure">Fig&#160;15-16</span>). See Table&#160;15-6 for additional intraoperative complications in EK.</p>
			<p class="h2">Postoperative Care and Complications</p>
			<p class="h3-h2">Dislocation or decentration of the donor graft</p>
			<p class="body-text--no-indent-">In DSEK and DMEK, the donor tissue should be well centered over the pupil, without fluid in the interface. To promote tissue adherence over the ensuing days, 40%–60% of the air bubble injected intraoperatively should remain after DSEK on postoperative day&#160;1 (<span class="xref-figure">Fig&#160;15-17</span>), and 80% of the gas (SF<span class="subscript CharOverride-1">6</span>) or air bubble should remain after DMEK on day&#160;1 (<span class="xref-figure">Fig&#160;15-18</span>). <br />The air bubble resorbs within 2–3&#160;days, and SF<span class="subscript CharOverride-1">6</span> resorbs within 4–6&#160;days after DMEK. The rate of dislocation of donor tissue decreases for both DSEK and DMEK as surgeon experience increases. See Table&#160;15-8 for dislocation rates for DSAEK and DMEK.</p>
			<p class="h4-text"><span class="h4-head">DSEK</span> Dislocation or decentration of the donor graft (<span class="xref-figure">Fig&#160;15-19</span>) typically occurs within the first 24&#160;hours after DSEK. A soft eye due to a preexisting tube shunt or uncontrolled release of the air increases the likelihood of a decentered or dislocated graft. Retained viscoelastic or the presence of vitreous in the interface may prevent proper adherence of the graft. If the graft remains attached on postoperative day&#160;1, subsequent dislocation is unlikely, although inadvertent trauma or eye rubbing during the first week may displace the donor tissue. Wearing glasses or a shield to protect the eye is recommended, along with exercising caution during instillation of eyedrops.</p>
			<p class="body-text">It is still not clear how long the air bubble should be retained after DSEK, as some surgeons remove the air completely on the day of surgery without an increased incidence of tissue dislocation. This raises the possibility that long-term retention of an air bubble is not necessary for graft adherence in DSEK.</p>
			<p class="h4-text"><span class="h4-head">DMEK</span> The donor tissue is more delicate, and as a result, peripheral or central detachments are much more common in DMEK than in DSEK (<span class="xref-figure">Fig&#160;15-20</span>). Anterior segment OCT allows visualization of the area of detachment (<span class="xref-figure">Fig&#160;15-21</span>). Peripheral detachments not involving the visual axis can be observed over several weeks to ensure there is no progression. They usually seal without adverse impact.</p>
			<p class="body-text">If the graft detachment extends into the visual axis or is greater than one-third of the graft area, the surgeon may consider additional injection of air (rebubbling) to tamponade the graft against the host. Initially, rebubbling was not advised because of reports of extensive, visually significant detachments resolving spontaneously. Yet longer-&#173;term follow-&#173;up of these cases has been instructive. Baydoun et al reported that, in patients with clinically significant graft detachments managed without rebubbling, there was a significant reduction in endothelial cell counts at 5-year follow-&#173;up, which led to a higher rate of late graft failure. In some cases, permanent stromal haze developed secondary to chronic corneal edema, worsening the visual outcome after repeated DMEK. Thus, early rebubbling seems to be the best course in these cases. If rebubbling is necessary, it can be performed in the office or surgery center.</p>
			<p class="body-text">In the event that the graft is attached but the cornea still has visually significant edema after 1–2&#160;months, repeated surgery is indicated prior to the development of chronic corneal edema, which can lead to bullous keratopathy, epithelial breakdown, and possible secondary infection. Repeated EK, either DMEK or DSEK, before the development of permanent corneal changes has a good visual prognosis, similar to that of the original procedure.</p>
			<p class="reference-first">Baydoun L, Ham L, Borderie V, et al. Endothelial survival after Descemet membrane endothelial keratoplasty. Effect of surgical indication and graft adherence status. <span class="italic">JAMA Ophthalmol.</span> 2015;133(1):1277–1285.</p>
			<p class="reference-mid">Baydoun L, van Dijk K, Dapena I, et al. Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty. <span class="italic">Ophthalmology.</span> 2015;122(1):8–16.</p>
			<p class="reference-mid">Dirisamer M, van Dijk K, Dapena I, et al. Prevention and management of graft detachment in Descemet membrane endothelial keratoplasty. <span class="italic">Arch Ophthalmol.</span> 2012;130(3):280–291.</p>
			<p class="reference-mid">Lehman RE, Copeland LA, Stock EM, Fulcher SF. Graft detachment rate in DSEK/DSAEK after same-day complete air removal. <span class="italic">Cornea.</span> 2015;34(11):1358–1361.</p>
			<p class="reference-last--no-space-">Price FW Jr, Price MO. To intervene or not to intervene: that is the question. <span class="italic">Ophthalmology.</span> 2015;122(1):6–7.</p>
			<p class="h3">Pupillary block</p>
			<p class="body-text--no-indent-">Anterior pupillary block or iris bombé may occur if the anterior chamber bubble migrates posteriorly, preventing aqueous flow through the pupil; <span class="xref-figure">Figures&#160;15-22</span> and <span class="xref-figure">15-23</span> show such a block after DSEK and DMEK, respectively. The resultant acute rise in IOP produces pain and can exacerbate preexisting optic nerve damage. Pupillary block may also lead to iridocorneal adhesion, damaging the graft and increasing the risk of rejection. Pupil dilation and supine positioning may relieve the pupil block; if this fails, some air should be removed. An inferior iridectomy performed prior to or at the time of the surgery reduces the likelihood of this scenario.</p>
			<p class="h3">Epithelial ingrowth</p>
			<p class="body-text--no-indent-">Epithelial ingrowth following DSEK can be seen as a gray-white deposit within the graft–host interface (<span class="xref-figure">Fig&#160;15-24</span>). It typically remains stable and is asymptomatic unless it occurs in the visual axis. The source of epithelium may be either the host or the donor. Host epithelium can be pushed into the eye through the main wound, side ports, or venting incisions used to drain interface fluid. It can also enter the eye through a fistulous track. Loose donor epithelium may enter the eye if adherent to the donor corneal button because of eccentric trephination beyond the microkeratome excision. In rare cases, epithelial ingrowth leads to graft failure that is missed on clinical examination but recognized on histologic examination of the tissue after removal. In a large series of cases, the majority of patients with epithelial ingrowth were simply observed and continued to see well without further intervention. In the atypical cases that resulted in graft failure, a second DSEK or PK produced a good outcome without recurrent ingrowth. This is in contrast to the progressive and devastating course of intraocular epithelial downgrowth associated with intracapsular cataract extraction or full-&#173;thickness PK. Epithelial ingrowth has not been described in DMEK.</p>
			<p class="reference-first ParaOverride-9">Dalal RR, Raber I, Dunn SP, et al. Epithelial ingrowth following endothelial keratoplasty. <span class="italic">Cornea.</span> 2016;35(4):465–470.</p>
			<p class="reference-last--no-space-">Suh LH, Shousha MA, Ventura RU, et al. Epithelial ingrowth after Descemet stripping automated endothelial keratoplasty: description of cases and assessment with anterior segment optical coherence tomography. <span class="italic">Cornea.</span> 2011;30(5):528–534.</p>
			<p class="h3">Other interface pathology</p>
			<p class="body-text--no-indent-">Infections can occur in the graft–host interface by several means: pathogens passing through venting incisions, contaminated donor tissue, or bacteria from the ocular surface dragged into the eye during insertion.</p>
			<p class="body-text">In a recent review by the EBAA, 0.7% of donor rim cultures were positive for fungi, and infections developed in 17.1% of corneas with positive fungal rim culture results. The incidence of postoperative fungal infections is significantly higher for EK than PK. These infections have occurred primarily in eyes that have undergone DSEK, but there are case reports of infections after DMEK as well. It is possible that these infections are related to the tissue warming that occurs during preparation of donor tissue for EK.</p>
			<p class="body-text">Interface opacification may occur because of retention of fibers, incomplete removal of the Descemet membrane, and persistence of interface fluid. <span class="italic">Textural interface opacity</span> describes a recently reported finding that results from retained viscoelastic or from the shearing of stromal fibrils during an irregular microkeratome donor preparation. The opacity has 2&#160;forms: elongated (a lacy honeycomb pattern of deposits with intervening clear zones) (<span class="xref-figure">Fig&#160;15-25</span>) and punctate (small, discrete deposits). Textural interface opacity may be associated with reduced vision, but it typically improves or disappears completely over many months. There have been no reports of interface problems after DMEK.</p>
			<p class="reference-first ParaOverride-14">Aldave A. The utility of donor corneal rim culture: a report of the EBAA Medical Advisory Board Subcommittee on fungal infection following corneal transplantation. <span class="italic">Subspecialty Day Program: Cornea.</span> Las Vegas: American Academy of Ophthalmology; 2015.</p>
			<p class="reference-last--no-space-">Vira S, Shih CY, Ragusa N, et al. Textural interface opacity after Descemet stripping automated endothelial keratoplasty: a report of 30&#160;cases and possible etiology. <span class="italic">Cornea.</span> 2013;<br />32(5):e54–59.</p>
			<p class="h3">Progression of cataracts</p>
			<p class="body-text--no-indent-">DSEK performed in a phakic eye may induce cataract progression, particularly in patients with narrow anterior chambers (&lt;3.0&#160;mm); therefore, DSEK with cataract extraction has been recommended in patients older than 50&#160;years or in the presence of mild to moderate cataract. In a large series of patients with Fuchs dystrophy, DSEK combined with cataract extraction did not increase the risk of graft dislocation, endothelial cell loss, or other complications. There has not been a similar study in patients after DMEK, but many surgeons routinely combine DMEK with cataract surgery.</p>
			<p class="reference-first">Terry MA, Shamie N, Chen ES, et al. Endothelial keratoplasty for Fuchs’ dystrophy with cataract: complications and clinical results with the new triple procedure. <span class="italic">Ophthalmology.</span> 2009;116(4):631–639.</p>
			<p class="reference-last--no-space-">Tsui JY, Goins KM, Sutphin JE, Wagoner MD. Phakic Descemet stripping automated endothelial keratoplasty: prevalence and prognostic impact of postoperative cataracts. <span class="italic">Cornea.</span> 2011;30(3):291–295.</p>
			<p class="h3">Primary graft failure</p>
			<p class="body-text--no-indent-">In published reports, the primary graft failure rates for DSEK and DMEK range from 2.2% to 8.0%, with a mean of 5.0% for DSEK (see Table&#160;15-8); higher rates are associated with less &#173;experienced surgeons. The lower rates probably reflect better surgical technique, which results in less tissue manipulation and a lower rate of graft dislocations and thus less endothelial trauma.</p>
			<p class="h3">Graft rejection</p>
			<p class="body-text--no-indent-">The incidence of corneal graft rejection following DSEK seems to be lower than that after PK; in several long-term studies, the incidence was between 0% and 10% in the first year, increasing slightly at 2&#160;years. In a paper by Wu et al, the incidence of graft rejection in DSEK was reported to be 22% at 5&#160;years, although this result may be skewed, as these investigators routinely discontinued steroids, in some cases at 4&#160;months postoperatively and typically at 1&#160;year. In contrast, in a study by Ratanasit and Gorovoy, where all patients were maintained on topical steroids indefinitely, the rejection rate was 2% after 5&#160;years in 51&#160;eyes. Several studies on graft rejection after DSEK suggest that long-term prophylaxis with a steroid once daily, regardless of the strength of the steroid, is important in reducing the incidence of graft rejection.</p>
			<p class="body-text">For DSEK patients, topical steroids such as prednisolone acetate (1%) 4&#160;times a day are prescribed initially and then tapered over time to once per day at 1&#160;year. A patient who is pseudophakic and not at risk of IOP elevation can continue to use a topical steroid once daily indefinitely, but periodic IOP measurement is recommended. If the patient is a steroid responder, loteprednol etabonate or fluorometholone may be substituted.</p>
			<p class="body-text">The clinical presentation of graft rejection in DSEK patients differs from that in PK patients. The classic endothelial rejection line of PK is not seen; instead, multiple keratic precipitates scattered across the cornea are typically noted (<span class="xref-figure">Fig&#160;15-26</span>).</p>
			<p class="body-text">The rate of graft rejection after DMEK seems to be even lower than that after DSEK (eg, less than 1%). Further, the medication regimen after DMEK offers more flexibility in terms of dosage, strength, and tapering of the topical steroids. In a randomized prospective study, prednisolone acetate 1% was used for only 1&#160;month following DMEK, after which loteprednol etabonate 0.5% gel was used without increased incidence of graft rejection. The authors of that study report that the incidence of graft rejection was 0% for patients who continued using topical steroids through the second year but increased to 6% in the second year in patients who stopped the steroids after 1&#160;year. The graft rejections experienced were mild and asymptomatic, and all but one reversed with resumption of steroid therapy.</p>
			<p class="reference-first ParaOverride-14">Anshu A, Price MO, Price FW Jr. Risk of corneal transplant rejection significantly reduced with Descemet’s membrane endothelial keratoplasty. <span class="italic">Ophthalmology.</span> 2012;119(3):536–540.</p>
			<p class="reference-mid">Dapena I, Ham L, Netuková M, van der Wees J, Melles GR. Incidence of early allograft rejection after Descemet membrane endothelial keratoplasty. <span class="italic">Cornea.</span> 2011;30(12):1341–1345.</p>
			<p class="reference-mid">Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol etabonate 0.5% gel vs prednisolone acetate 1% solution after Descemet membrane endothelial keratoplasty: prospective randomized trial. <span class="italic">Cornea.</span> 2015;34(8):853–858.</p>
			<p class="reference-mid">Price MO, Scanameo A, Feng MT, Price FW Jr. Descemet’s membrane endothelial keratoplasty: risk of immunologic rejection episodes after discontinuing topical corticosteroids. <span class="italic">Ophthalmology.</span> 2016;123(6):1232–1236.</p>
			<p class="reference-mid">Ratanasit A, Gorovoy MS. Long-term results of Descemet stripping automated endothelial keratoplasty. <span class="italic">Cornea.</span> 2011;30(12):1414–1418.</p>
			<p class="reference-last--no-space-">Wu EI, Ritterband DC, Yu G, Shields RA, Seedor JA. Graft rejection following Descemet stripping automated endothelial keratoplasty: features, risk factors, and outcomes. <span class="italic">Am&#160;J Ophthalmol.</span> 2012;153(5):949–957.</p>
			<p class="h3 ParaOverride-19">Endothelial cell loss</p>
			<p class="body-text--no-indent-">Several maneuvers potentially contribute to early endothelial cell loss in EK patients, including the manipulation of tissue entailed in the preparation of donor tissue, placement and orientation of the tissue within the anterior chamber, primary injection of air to facilitate graft adherence, and rebubbling and tissue manipulation to treat dislocated grafts. Endothelial cell loss at 1&#160;year for both DSEK and DMEK is reported to be approximately 32%–37%. In a follow-&#173;up study of 95&#160;eyes by Price and colleagues, the median endothelial cell loss was 53% at 5&#160;years and 71% at 10&#160;years, which compares favorably to results for PK in the Cornea Donor Study, which showed a mean cell loss of 70% at 5&#160;years and 76% at 10&#160;years. Long-term viability of the endothelial cells is influenced by ocular comorbidity such as previous filtering surgery and, in particular, tube shunts. Long-term prospective trials on DMEK and DSEK are necessary to better understand the clinical biology of the corneal endothelium and the impact of endothelial cell loss on graft viability.</p>
			<p class="reference-first ParaOverride-14">Li JY, Terry MA, Goshe J, Shamie N, Davis-&#173;Boozer D. Graft rejection after Descemet’s stripping automated endothelial keratoplasty: graft survival and endothelial cell loss. <span class="italic">Ophthalmology.</span> 2012;119(1):90–94.</p>
			<p class="reference-mid">Ni N, Sperling BJ, Dai Y, Hannush SB. Outcomes after Descemet stripping automated endothelial keratoplasty in patients with glaucoma drainage devices. <span class="italic">Cornea.</span> 2015;34(8):<br />870–875.</p>
			<p class="reference-mid">Price FW Jr, Feng MT, Price MO. Evolution of endothelial keratoplasty: where are we headed? <span class="italic">Cornea.</span> 2015;34(Suppl 10):S41–S47.</p>
			<p class="reference-mid">Price MO, Calhoun P, Kollman C, Price FW Jr, Lass JH. Descemet stripping endothelial keratoplasty: ten-year endothelial cell loss compared with penetrating keratoplasty. <span class="italic">Ophthalmology.</span> 2016;123(7):1421–1427.</p>
			<p class="reference-mid">Price MO, Fairchild KM, Price DA, Price FW Jr. Descemet’s stripping endothelial kerato&#173;plasty: five-year graft survival and endothelial cell loss. <span class="italic">Ophthalmology.</span> 2011;118(4):725–729.</p>
			<p class="reference-mid">Ratanasit A, Gorovoy MS. Long-term results of Descemet stripping automated endothelial keratoplasty. <span class="italic">Cornea.</span> 2011;30(12):1414–1418.</p>
			<p class="reference-last--no-space-">Sugar A. The importance of corneal endothelial cell survival after endothelial keratoplasty. <span class="italic">JAMA Ophthalmol.</span> 2015;133(11):1285–1286.</p>
			<p class="h2 ParaOverride-22">Novel Methods for Treatment of Endothelial Dysfunction</p>
			<p class="body-text--no-indent-">A number of case reports have described extensive, visually significant graft detachments; nonadherent, “free-&#173;floating,” grafts; and even an upside-&#173;down graft after DMEK in which the cornea cleared without additional intervention. The restoration of corneal clarity in these cases was thought to result from endothelial migration either from the peripheral cornea or from the free-&#173;floating donor tissue. After this experience, Dirisamer et al performed descemetorrhexis with implantation of a free-&#173;floating donor graft of Descemet membrane and endothelial cells, a technique called <span class="italic">Descemet membrane endothelial transfer (DMET).</span> In their study of 12&#160;patients (7&#160;patients with Fuchs endothelial corneal dystrophy [FECD] and 5 with pseudophakic bullous keratopathy [PBK]), all of the patients with FECD had clear corneas of normal thickness after 6&#160;months; however, the patients with PBK did not improve and required further surgery. The authors suggested that descemetorrhexis in the patients with FECD, removing the thickened Descemet membrane characteristic of FECD, allowed the migration of endothelial cells from either the host or donor endothelial cells. In contrast, the corneal edema did not resolve in PBK because there was endothelial depletion in the host cornea.</p>
			<p class="body-text">Subsequently, other investigators attempted a standard descemetorrhexis of <br />8.0–8.5&#160;mm without placement of donor tissue in patients with FECD. The results of this technique have been mixed, with some surgeons abandoning the procedure and some investigators continuing to look for ways to modify it for a more consistent and successful outcome. In one study of 13&#160;eyes, the investigators opted to decrease the size of the central descemetorrhexis to 4&#160;mm. Corneal edema was present in all 13&#160;eyes in the immediate postoperative period. Four eyes were classified as fast responders, with resolution of the corneal edema occurring at 1&#160;month, and 4&#160;eyes were considered typical responders, with corneal clearing at 3&#160;months. Two eyes were slow responders, with partial corneal clearing, and 3&#160;eyes required EK. In the future, a pharmacologic approach such as the use of Rho-&#173;associated kinase inhibitors to induce host endothelial proliferation or endothelial cell culture using reprogrammed adult stem cells from the patient may improve the success of this descemetorrhexis without the use of donor tissue.</p>
			<p class="body-text">In an effort to expand the pool of donor tissue, a new technique has been introduced in which a single donor corneal button is divided into 2&#160;segments for transplantation in 2&#160;different patients. This technique, referred to as <span class="italic">hemi-DMEK,</span> may not be adopted in the United States because of regulatory, billing, and liability challenges, but it may be more acceptable in areas where there are donor shortages.</p>
			<p class="reference-first">Arbelaez JG, Price MO, Price FW Jr. Long-term follow-&#173;up and complications of stripping Descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. <span class="italic">Cornea.</span> 2014;33(12):1295–1299.</p>
			<p class="reference-mid">Borkar DS, Veldman P, Colby KA. Treatment of Fuchs endothelial dystrophy by Descemet stripping without endothelial keratoplasty. <span class="italic">Cornea.</span> 2016;35(10):1267–1273.</p>
			<p class="reference-mid">Dirisamer M, Ham L, Dapena I, van Dijk K, Melles GR. Descemet membrane endothelial transfer: “free-&#173;floating” donor Descemet implantation as a potential alternative to “keratoplasty.” <span class="italic">Cornea.</span> 2012;31(2):194–197.</p>
			<p class="reference-mid">Dirisamer M, Yeh RY, van Dijk K, Ham L, Dapena I, Melles GR. Recipient endothelium may relate to corneal clearance in Descemet membrane endothelial transfer. <span class="italic">Am&#160;J Ophthalmol.</span> 2012;154(2):290–296.</p>
			<p class="reference-mid">Koenig SB. Planned descemetorhexis without endothelial keratoplasty in eyes with Fuchs corneal endothelial dystrophy. <span class="italic">Cornea.</span> 2015;34(9):1149–1151.</p>
			<p class="reference-last--no-space-">Lam FC, Baydoun L, Satué M, Dirisamer M, Ham L, Melles GR. One-year outcome of hemi-&#173;Descemet membrane endothelial keratoplasty. <span class="italic">Graefes Arch Clin Exp Ophthalmol.</span> 2015;<br />253(11):1955–1958.</p>
			</div>
			<p class="h1 ParaOverride-20">Pediatric Corneal Transplantation</p>
			<div id="Chapt15_Top8">
			<p class="body-text--no-indent-">Increased understanding of the special problems associated with pediatric grafts, advances in preoperative diagnostic techniques and in surgical methods, and improved postoperative management have enhanced the visual prognosis for children who have undergone corneal transplantation. Further, improvements in pediatric anesthesia and the recognition that development of amblyopia is a major impediment to useful vision have led to earlier surgical intervention. The success rate of pediatric corneal transplantation depends on the extent of coexisting ocular abnormalities. For example, one of the most common indications for pediatric keratoplasty is Peters anomaly. For type&#160;I disease, in which there is a central corneal opacity and a normal anterior segment, the survival rate for a clear graft was 83%–90% in 1&#160;large series (mean follow-&#173;up time of 78&#160;months), depending on the age of the patient at the time of surgery. By contrast, in another large series of patients with either type&#160;I or type&#160;II Peters anomaly, the outcomes were significantly worse: only 56% of grafts remained clear at 6&#160;months; 44%, at 3&#160;years. This was attributed to the inclusion of patients with type&#160;II disease, in which the anterior segment findings are more severe and characteristically include adhesions among the cornea, iris, and lens; corneal neovascularization; glaucoma; cataract; and corneal staphyloma. Therefore, more extensive surgery was required, and not surprisingly, the survival rate of the graft decreased.</p>
			<p class="body-text">Critical to a successful outcome is the family’s (or caregiver’s) dedication to following a rigorous postoperative regimen, which includes repeated examinations under anesthesia and adherence to the medication regimen. Postoperative glaucoma, strabismus, self-&#173;induced trauma, and immune rejection are common. As part of obtaining informed consent from the family, the physician must discuss the many difficult issues associated with the surgery, including the complicated postoperative course, loss of time from work (with associated loss of income), the extensive ongoing care required for the child, disruption of home life, and less time to devote to other dependents.</p>
			<p class="body-text">Corneal grafting in children younger than 2&#160;years is associated with rapid neovascularization, especially along the sutures. As the wound heals, erosions may occur along the sutures, leading to eye rubbing, epithelial defects, mucus accumulation, and possible infection. Suture erosion has been reported to occur as early as 2&#160;weeks postoperatively in infants and necessitates urgent and frequent examination under anesthesia in the operating room to evaluate the transplant and remove sutures until all have been removed. In addition, early fitting with a contact lens (as early as the time of PK) and ocular occlusive therapy are necessary to stem development of amblyopia in children with monocular aphakia.</p>
			<p class="body-text">Surgeons have become aware of DALK as an option for certain pediatric patients with stromal scarring without any other corneal pathology. For disease that is primarily endothelial, such as congenital hereditary endothelial dystrophy, EK has been reported to provide good outcomes, as observed in a small series of 8&#160;patients (15&#160;eyes).</p>
			<p class="reference-first ParaOverride-9">Busin M, Beltz J, Scorcia V. Descemet-&#173;stripping automated endothelial keratoplasty for congenital hereditary endothelial dystrophy. <span class="italic">Arch Ophthalmol.</span> 2011;129(9):1140–1146.</p>
			<p class="reference-mid">Nischal KK. Pediatric keratoplasty. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1382–1398.</p>
			<p class="reference-mid">Rao KV, Fernandes M, Gangopadhyay N, Vemuganti GK, Krishnaiah S, Sangwan VS. Outcome of penetrating keratoplasty for Peters anomaly. <span class="italic">Cornea.</span> 2008;27(7):749–753.</p>
			<p class="reference-last--no-space-">Zaidman GW, Flanagan JK, Furey CC. Long-term visual prognosis in children after corneal transplant surgery for Peters anomaly type&#160;I. <span class="italic">Am&#160;J Ophthalmol.</span> 2007;144(1):104–108.</p>
			</div>
			<p class="h1 ParaOverride-23">Corneal Autograft Procedures</p>
			<div id="Chapt15_Top9">
			<p class="body-text--no-indent-">The greatest advantage of a corneal autograft is the elimination of allograft rejection. Cases with clinical circumstances appropriate for autograft are uncommon, but an astute ophthalmologist who recognizes the potential for a successful autograft procedure can spare the patient the risks associated with long-term topical steroid use and the need for lifelong vigilance against rejection.</p>
			<p class="body-text">A <span class="italic">rotational</span> autograft can be used to reposition a localized corneal scar that involves the pupillary axis. By making an eccentric trephination and rotating the host corneal button before resuturing, the surgeon can place a paracentral zone of clear cornea in the pupillary axis. The procedure is particularly useful in children, in whom the prognosis for PK is poorer, and in areas with tissue scarcity. It is important that the graft–host junction not be too close to the visual axis, because image distortion and irregular astigmatism could result.</p>
			<p class="body-text">A <span class="italic">contralateral</span> autograft is reserved for patients who have a corneal opacity in one eye with a favorable visual prognosis, and a clear cornea in the opposite eye with coexisting severe dysfunction of the afferent system (eg, retinal detachment, severe amblyopia). The clear cornea is transplanted to the first eye; then, it is replaced with either the diseased cornea from the first eye or an allograft. If an eye with a clear cornea is to be enucleated or eviscerated, the cornea can be used as a donor for keratoplasty in the fellow eye. Such simultaneous bilateral transplant surgery carries the risk of bilateral endophthalmitis.</p>
			</div>
			<p class="h1">Keratoprosthesis</p>
			<div id="Chapt15_Top10">
			<p class="body-text--no-indent-">In some patients, corneal transplantation is associated with an extremely guarded prognosis because of a history of multiple graft failures or associated ocular surface disease (eg, chronic bilateral inflammation from Stevens-&#173;Johnson syndrome or mucous membrane pemphigoid). These patients may be good candidates for a synthetic keratoprosthesis. Claes Dohlman, a pioneer in the development of the keratoprosthesis, divides these high-risk patients into 2&#160;groups: those with a good blink reflex and adequate tear function and those with significant conjunctival scarring, dry eye, and exposure. In the first group of patients, the Boston keratoprosthesis type&#160;I (KPro; Massachusetts Eye and Ear Infirmary, Boston) works well (<span class="xref-figure">Fig&#160;15-27</span>). For patients with end-stage dry eye, the Boston KPro type&#160;II is an option. Other types of keratoprostheses for these high-risk patients are more popular in Europe and include the TKPro, which uses tibia bone tissue, and the osteo-odonto-&#173;keratoprosthesis, which uses dentine and alveolar bone tissue.</p>
			<p class="body-text">Some surgeons have expanded the indications to include the treatment of ocular trauma, advanced quiescent herpetic disease, aniridia, and congenital corneal opacification.</p>
			<p class="body-text">The prognosis for keratoprosthesis implantation has improved dramatically because of innovations in the design of keratoprostheses and improvements in postoperative management. The use of a soft contact lens and long-term prophylactic antibiotics has reduced the incidence of infection and necrosis around the keratoprosthesis. A review of the literature on the Boston keratoprosthesis, the results of which were published in a report by AAO, revealed that a BCSVA of 20/200 or better occurred in 45%–89% of eyes, and a BCSVA of 20/40 or better occurred in 11%–39% of eyes after implantation of the Boston KPro. In a large, multicenter study of 300&#160;eyes followed for 17.1±14.8&#160;months after implantation of the Boston KPro, there was significant improvement in vision, although only 6% of eyes had visual acuity of 20/60 or better. The retention rate with the Boston KPro type&#160;I ranged from 65% to 100%. Loss of vision resulted from corneal melts due to exposure keratopathy, endophthalmitis, infectious keratitis, or corneal ulceration. The most common complications following keratoprosthesis implantation were persistent epithelial defects, retroprosthetic membrane formation, stromal necrosis, and elevated IOP, often associated with glaucoma (<span class="xref-table">Table&#160;15-9</span>).</p>
			<p class="reference-first">Chang HY, Luo ZK, Chodosh J, Dohlman CH, Colby KA. Primary implantation of type&#160;I Boston keratoprosthesis in nonautoimmune corneal disease. <span class="italic">Cornea.</span> 2015;34(3):264–270.</p>
			<p class="reference-mid">Lee WB, Shtein RM, Kaufman SC, Deng SX, Rosenblatt MI. Boston keratoprosthesis: outcomes and complications: a report by the American Academy of Ophthalmology. <span class="italic">Ophthalmology.</span> 2015;122(7):1504–1511.</p>
			<p class="reference-mid">Part XII, Keratoprosthesis. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;2. 4th&#160;ed. Philadelphia: Elsevier; 2017:1635–1667.</p>
			<p class="reference-mid">Rudnisky CJ, Belin MW, Guo R, Ciolino JB; Boston Type&#160;1 Keratoprosthesis Study Group. Visual acuity outcomes of the Boston keratoprosthesis type&#160;1: multicenter study results. <span class="italic">Am&#160;J Ophthalmol.</span> 2016;162:89–98.</p>
			<p class="reference-last--no-space-">Sayegh RR, Afshari NA, Chang HP, Lou ZK, Chodosh J. An overview of keratoprosthesis. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Academy of Ophthalmology; 2014, module&#160;6.</p>
		</div>
		</div>
		<div id="_idContainer012" class="Basic-Text-Frame">
			<table id="table001" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 15-1</span> Contemporary Keratectomy and Keratoplasty Procedures</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Acronym</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Procedure</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">ALK (ALTK)</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Anterior lamellar keratoplasty (therapeutic)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">DALK</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Deep anterior lamellar keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">DLEK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Deep lamellar endothelial keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">DMEK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Descemet membrane endothelial keratoplasty (automated)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">DSEK (DSAEK)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Descemet stripping endothelial keratoplasty (automated)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">EK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Endothelial keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">FALK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Femtosecond anterior lamellar keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">FLAK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Femtosecond laser–assisted keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">PKP/PK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Penetrating keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">PRK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Photorefractive keratectomy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">PTK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Phototherapeutic keratectomy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">SK</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Superficial keratectomy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-7" colspan="3">
							<p class="table-source-note">Modified from American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="CharOverride-3">Corneal Edema and Opacification.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer013" class="Basic-Text-Frame">
			<table id="table002" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-9" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-15" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="15">
							<p class="table-title"><span class="table-number">Table 15-2</span> Indications for Transplant in US and International Eye Banks, 2016</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-8" colspan="15">
							<p class="table-subhead">Endothelial Cell Failure</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-9">
							<p class="table-column-head">Surgical Diagnosis</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">PK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">ALK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">EK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-subhead">Total</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body">Post–cataract surgery edema</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">2729</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">33.0%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">5558</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">67.0%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">8287</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Fuchs dystrophy</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1171</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">6.9%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">15,845</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">93.1%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">17,016</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Other causes of endothelial dysfunction</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1035</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">26.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">2882</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">74.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">3917</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="CharOverride-4">Subtotal</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">4935</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">17.0%</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">0</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">0%</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">24,285</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">83.0%</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">29,220</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10" colspan="3">
							<p class="table-body ParaOverride-26">12.8% of PK</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10" colspan="3" />
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10" colspan="3">
							<p class="table-body ParaOverride-25">75.4% of EK</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-25">40% of grafts</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
			<table id="table003" class="Basic-Table TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-9" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-15" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11" colspan="15">
							<p class="table-title"><span class="table-number">Table 15-2</span> <span class="CharOverride-3">(continued)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-12" colspan="15">
							<p class="table-subhead">Stromal or Full-Thickness (Nonendothelial) Disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-9">
							<p class="table-column-head">Surgical Diagnosis</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">PK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">ALK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">EK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-subhead">Total</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body">Keratoconus</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">5463</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">88.0%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">732</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">12.0%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">6195</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Other degenerations or dystrophies</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1164</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">93.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">88</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">7.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1252</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Post–refractive surgery</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">70</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">94.6%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">4</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">5.4%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">74</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Microbial changes</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">677</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">95.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">36</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">5.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">713</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Mechanical or chemical trauma</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">982</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">97.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">31</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">3.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1013</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Congenital opacities</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">620</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">96.1%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">25</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">3.9%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">645</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Pterygium</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">10</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">77.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">3</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">23.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">13</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Noninfectious ulcerative keratitis or perforations</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1301</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">95.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">62</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">4.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">1363</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Other causes of corneal dysfunction or distortion</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">2346</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">92.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">191</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">7.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">—</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24">2537</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="CharOverride-4">Subtotal</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">12,633</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">91.5%</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">1172</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">8.5%</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">0</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">0%</span></p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">13,805</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-26">32.9% of PK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-25">49.1% of ALK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3" />
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13">
							<p class="table-body">18.9% of grafts</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-14" colspan="15">
							<p class="table-subhead">Regraft</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-9">
							<p class="table-column-head">Surgical Diagnosis</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">PK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">ALK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">EK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-subhead">Total</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body">Repeated corneal transplant</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">4529</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">61.3%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">38</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">0.5%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">2822</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">38.2%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">7389</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-26">11.8% of PK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-25">1.6% of ALK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-25">8.7% of EK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13">
							<p class="table-body">10.1% of grafts</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-14" colspan="15">
							<p class="table-subhead">Unknown/Unspecified</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-9">
							<p class="table-column-head">Surgical Diagnosis</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">PK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">ALK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9" colspan="3">
							<p class="table-subhead">EK</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-subhead">Total</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body">Unknown, unreported, or unspecified</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">16,316</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-24">72.2%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">1176</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">5.2%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">5114</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">22.6%</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-25">22,606</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-24">42.5% of PK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-25">49.3% of ALK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13" colspan="3">
							<p class="table-body ParaOverride-25">15.9% of EK</p>
						</td>
						<td class="Basic-Table CellOverride-13" />
						<td class="Basic-Table CellOverride-13">
							<p class="table-body">31.0% of grafts</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-15" />
						<td class="Basic-Table CellOverride-15" />
						<td class="Basic-Table CellOverride-15" colspan="3">
							<p class="table-subhead">PK</p>
						</td>
						<td class="Basic-Table CellOverride-15" />
						<td class="Basic-Table CellOverride-15" colspan="3">
							<p class="table-subhead">ALK</p>
						</td>
						<td class="Basic-Table CellOverride-15" />
						<td class="Basic-Table CellOverride-15" colspan="3">
							<p class="table-subhead">EK</p>
						</td>
						<td class="Basic-Table CellOverride-15" />
						<td class="Basic-Table CellOverride-15">
							<p class="table-subhead">Total</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-20">
						<td class="Basic-Table CellOverride-16">
							<p class="table-body"><span class="CharOverride-4">Total for each procedure</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">38,413</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-24"><span class="CharOverride-4">52.6%</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">2386</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">3.3%</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">32,221</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">44.1%</span></p>
						</td>
						<td class="Basic-Table CellOverride-16" />
						<td class="Basic-Table CellOverride-16">
							<p class="table-body ParaOverride-25"><span class="CharOverride-4">73,020</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-21">
						<td class="Basic-Table CellOverride-7" colspan="15">
							<p class="table-source-note">Modified with permission from the Eye Bank Association of America (EBAA). <span class="CharOverride-3">2016</span><span class="CharOverride-3"> Eye Banking Statistical Report.</span> Washington, DC: EBAA; 2017.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer015" class="Basic-Text-Frame">
			<table id="table004" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-22" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-17">
							<p class="table-title"><span class="table-number">Table 15-3</span> Medical Criteria Contraindicating Donor-Cornea Use</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Death of unknown cause with likelihood of other exclusion criteria</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Congenital rubella</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Reye syndrome within the past 3 months</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Active viral encephalitis of unknown origin or progressive encephalopathy (eg, subacute sclerosing panencephalitis, progressive multifocal leukoencephalopathy)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Active bacterial or viral encephalitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Active bacterial or fungal endocarditis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Suspected rabies virus infection or history of being bitten, within the past 6 months, by an animal suspected to be infected with rabies virus</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Down syndrome (exclusion criterion for PK or ALK)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Intrinsic eye diseases</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Retinoblastoma</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Malignant tumor of the anterior ocular segment or known adenocarcinoma in the eye (primary or metastatic origin)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Active ocular or intraocular inflammation: conjunctivitis, keratitis, scleritis, anterior uveitis, uveitis, vitreitis, choroiditis, or retinitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Congenital or acquired disorders of the eye that would preclude a successful outcome for the intended use (eg, a central donor corneal scar for an intended PK, keratoconus, or keratoglobus)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Leukemias</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Active disseminated lymphomas</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">High-risk behavior or incarceration in prison</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Prior refractive corneal surgery, such as radial keratotomy, PRK, LASIK, and lamellar inserts, with the exception that previous laser refractive surgery may not disqualify a donor’s tissue for use in EK</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Positive test for anti-HIV-1 and anti-HIV-2 (or combination test) and nonreactive for HBsAg and anti-HCV antibody</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">History of Ebola virus disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">History of melanoma with known metastatic disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-18">
							<p class="table-head">Donors for PK </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Prior intraocular or anterior segment surgery</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Refractive corneal procedures (radial keratotomy, lamellar inserts)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Laser photoablation surgery</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Pterygium or other disorders involving the optical center of the cornea</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-18">
							<p class="table-head">Donors for ALK </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Criteria are the same as those listed for PK, except that tissue with local eye disease affecting the corneal endothelium or previous ocular surgery that does not compromise the corneal stroma can be used.</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-18">
							<p class="table-head">Donors for EK </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Criteria are the same as those listed for PK, except that tissue with noninfectious anterior pathology that does not affect the posterior stroma and endothelium is acceptable.</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-24">
						<td class="Basic-Table CellOverride-7">
							<p class="table-source-note">HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HIV = human immunodeficiency virus; LASIK = laser in situ keratomileusis.</p>
							<p class="table-source-note">Information from the Eye Bank Association of America (EBAA). <span class="table-source-emphasis">EBAA Medical Standards, October 2016.</span> Washington, DC: EBAA; 2016.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer016" class="Basic-Text-Frame">
			<table id="table005" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-25" />
					<col class="_idGenTableRowColumn-26" />
					<col class="_idGenTableRowColumn-25" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-17" colspan="3">
							<p class="table-title"><span class="table-number">Table 15-4</span> Disease Transmission From Corneal Transplantation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"><span class="CharOverride-4">Proven disease transmission from corneal transplantation</span></p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Rabies</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Hepatitis B</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Creutzfeldt-Jakob disease (previously diagnosed)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Retinoblastoma</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Bacterial or fungal keratitis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Bacterial or fungal endophthalmitis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18">
							<p class="table-body"><span class="CharOverride-4">Potential disease transmission from corneal transplantation</span><span class="CharOverride-5">*</span></p>
						</td>
						<td class="Basic-Table CellOverride-18" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Human immunodeficiency virus infection</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Herpes simplex virus infection</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Prion diseases</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-24">
						<td class="Basic-Table CellOverride-7" colspan="3">
							<p class="table-footnote"><span class="table-superscript-note-ast-">*</span>&#9;Other diseases that contraindicate donor-cornea use and that could be transmitted via corneal transplantation are listed in Table 15-3.</p>
							<p class="table-source-note">Information from the Eye Bank Association of America (EBAA). <span class="table-source-emphasis">EBAA Medical Standards, October 2016.</span> Washington, DC: EBAA; 2016.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer019">
				<div id="_idContainer017" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-1</span> Corneal tissue preserved in Optisol GS. <span class="figure-source-note">(Courtesy of</span><span class="figure-source-note"> </span><span class="figure-source-note">Woodford S.</span><span class="figure-source-note"> </span><span class="figure-source-note">Van Meter, MD.)</span></p>
				</div>
				<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9492.jpg" alt="" />
				</div>
			</div>
		</div>
		<div id="_idContainer020" class="Basic-Text-Frame">
			<table id="table006" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-27" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-28" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-30" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-31" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-32" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-29" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="17">
							<p class="table-title"><span class="table-number">Table 15-5</span> Layer-Based Approach to the Surgical Management of Corneal Opacities and Edema</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Layer of Pathology</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Representative Disease</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">ED</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">SK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">PTK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">ALK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">DALK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">EK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">PK</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Epithelium</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Redundant, irregular epithelium</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-4" rowspan="2">
							<p class="table-body">Subepithelial layer</p>
						</td>
						<td class="Basic-Table CellOverride-4" rowspan="2" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Epithelial (anterior) basement membrane dystrophy</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Salzmann nodular degeneration</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" rowspan="2">
							<p class="table-body">Bowman layer</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="2" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Band keratopathy</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Reis-Bücklers dystrophy</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Anterior–midstroma</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Granular corneal dystrophy</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Midposterior stroma</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Scarring</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-25">•</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Endothelium</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-25">•</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-25">•</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-24">
						<td class="Basic-Table CellOverride-7" colspan="17">
							<p class="table-footnote">ED = epithelial debridement; SK = superficial keratectomy.</p>
							<p class="table-source-note">From American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="table-source-emphasis">Corneal Edema and Opacification.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer023">
				<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-7759.jpg" alt="" />
				</div>
				<div id="_idContainer022" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-2</span> Slit-lamp photograph of a full-&#173;thickness corneal transplant with interrupted and continuous 10-0&#160;nylon sutures. The interrupted sutures can be removed to control astigmatism. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer024" class="Basic-Text-Frame">
			<table id="table007" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-33" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-34" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-34" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-34" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-34" />
				</colgroup>
				<thead>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="9">
							<p class="table-title"><span class="table-number">Table 15-6</span> Comparison of Procedures for Penetrating and Selective Keratoplasty</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head">Penetrating Keratoplasty (PK)</p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head">Anterior Lamellar <br />Keratoplasty (ALK)</p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head">Deep Anterior Lamellar Keratoplasty (DALK)</p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head">Endothelial Keratoplasty <br />(DSEK/DMEK)</p>
						</td>
					</tr>
				</thead>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Indications</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Combined stromal or endothelial corneal pathology</p>
							<p class="table-body">Keratoconus</p>
							<p class="table-body">Concomitant IOL suturing/ anterior segment reconstruction</p>
							<p class="table-body">Fuchs corneal dystrophy/pseudophakic corneal edema (less frequently) </p>
							<p class="table-body">Corneal perforation treated with patch graft, either lamellar or full thickness</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Superficial stromal dystrophies and degenerations</p>
							<p class="table-body">Salzmann nodular degeneration</p>
							<p class="table-body">Scars, trauma, and dermoids</p>
							<p class="table-body">Infections</p>
							<p class="table-body">Superficial corneal tumors</p>
							<p class="table-body">Descemetocele</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Keratoconus</p>
							<p class="table-body">Infections</p>
							<p class="table-body">Corneal stromal dystrophies not involving endothelium</p>
							<p class="table-body">Corneal thinning</p>
							<p class="table-body">Corneal ectasia secondary to LASIK</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Fuchs corneal dystrophy</p>
							<p class="table-body">Posterior polymorphous corneal dystrophy</p>
							<p class="table-body">Congenital hereditary endothelial dystrophy </p>
							<p class="table-body">Pseudophakic corneal edema</p>
							<p class="table-body">ICE syndrome</p>
							<p class="table-body">Failed corneal graft</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-36">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Intraoperative complications</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Scleral perforation with fixation sutures</p>
							<p class="table-body">Expulsive or choroidal hemorrhage</p>
							<p class="table-body">Vitreous hemorrhage</p>
							<p class="table-body">Damage to lens or iris</p>
							<p class="table-body">Irregular trephination</p>
							<p class="table-body">Poor graft centration</p>
							<p class="table-body">Iris or vitreous incarceration in the wound </p>
							<p class="table-body">Torn posterior capsule</p>
							<p class="table-body">Damage to donor endothelium</p>
							<p class="table-body">Excessive bleeding from the iris or wound edge</p>
							<p class="table-body">Retained Descemet membrane</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Poor microkeratome dissection for donor tissue</p>
							<p class="table-body">Corneal perforation</p>
							<p class="table-body">Thin or irregular donor tissue</p>
							<p class="table-body">Irregular dissection of host  stromal tissue</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Corneal perforation requiring transition to PK</p>
							<p class="table-body">Difficulty obtaining smooth dissection to Descemet membrane</p>
							<p class="table-body">Pseudo–double anterior chamber or Descemet membrane detachment</p>
							<p class="table-body">Placement of an air bubble to tamponade Descemet membrane can cause formation of an anterior subcapsular cataract</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Poor microkeratome dissection of donor tissue (DSEK) or inability to harvest Descemet membrane with endothelium (DMEK)</p>
							<p class="table-body">Inability to strip host Descemet tissue</p>
							<p class="table-body">Improper orientation or loss of donor tissue</p>
							<p class="table-body">Excessive manipulation of donor tissue, leading to cell loss and possible graft failure</p>
							<p class="table-body">Tearing of donor tissue </p>
							<p class="table-body">Retention of viscoelastic </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">Intraoperative complications <span class="CharOverride-3">(cont&apos;d)</span></p>
						</td>
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">Retinal tear or detachment</p>
						</td>
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">Vitreous or blood in the interface </p>
							<p class="table-body">Choroidal hemorrhage (lower risk than in PK)</p>
							<p class="table-body">Hemorrhage leading to blood in the interface</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-38">
						<td class="Basic-Table CellOverride-22">
							<p class="table-body">Postoperative complications</p>
						</td>
						<td class="Basic-Table CellOverride-22" />
						<td class="Basic-Table CellOverride-22">
							<p class="table-body">Suture-related problems </p>
							<p class="table-body">Infectious keratitis </p>
							<p class="table-body">Neovascularization </p>
							<p class="table-body">Graft rejection</p>
							<p class="table-body">Graft failure</p>
							<p class="table-body">Wound leak/misalignment</p>
							<p class="table-body">Flat chamber</p>
							<p class="table-body">Glaucoma</p>
							<p class="table-body">Endophthalmitis</p>
							<p class="table-body">Cystoid macular edema</p>
							<p class="table-body">Elevated IOP</p>
							<p class="table-body">Persistent epithelial defect</p>
							<p class="table-body">Recurrent primary disease</p>
						</td>
						<td class="Basic-Table CellOverride-22" />
						<td class="Basic-Table CellOverride-22">
							<p class="table-body">Suture-related problems </p>
							<p class="table-body">Infectious keratitis </p>
							<p class="table-body">Neovascularization </p>
							<p class="table-body">Graft (stromal) rejection</p>
							<p class="table-body">Graft failure</p>
							<p class="table-body">Opacification and vascularization of the interface</p>
							<p class="table-body">Retained interface debris </p>
							<p class="table-body">Microbial infections</p>
						</td>
						<td class="Basic-Table CellOverride-22" />
						<td class="Basic-Table CellOverride-22">
							<p class="table-body">Suture-related problems </p>
							<p class="table-body">Infectious keratitis </p>
							<p class="table-body">Neovascularization </p>
							<p class="table-body">Epithelial or stromal allograft rejection</p>
							<p class="table-body">Graft failure</p>
							<p class="table-body">Opacification and/or vascularization of the interface</p>
							<p class="table-body">Inflammatory necrosis of the graft</p>
							<p class="table-body">Retained interface debris</p>
							<p class="table-body">Microbial infections</p>
							<p class="table-body">Visually significant wrinkling of Descemet membrane</p>
						</td>
						<td class="Basic-Table CellOverride-22" />
						<td class="Basic-Table CellOverride-22">
							<p class="table-body">Pupillary block glaucoma</p>
							<p class="table-body">Dislocation or decentration of lenticule </p>
							<p class="table-body">Primary graft failure</p>
							<p class="table-body">Epithelial ingrowth</p>
							<p class="table-body">Interface opacification</p>
							<p class="table-body">Graft rejection (lower risk than after PK)</p>
							<p class="table-body">Infection in the interface</p>
							<p class="table-body">Cystoid macular edema</p>
							<p class="table-body">Reduced endothelial cell survival</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-39">
						<td class="Basic-Table CellOverride-23">
							<p class="table-body">Advantages</p>
						</td>
						<td class="Basic-Table CellOverride-23" />
						<td class="Basic-Table CellOverride-23">
							<p class="table-body">Full-thickness tissue eliminates interface-related visual problems</p>
							<p class="table-body">Ability to treat epithelial, stromal, and endothelial disease and allow anterior segment reconstruction in a single procedure if necessary</p>
						</td>
						<td class="Basic-Table CellOverride-23" />
						<td class="Basic-Table CellOverride-23">
							<p class="table-body">Selective removal of pathologic tissue</p>
							<p class="table-body">Reduced risk of penetration of anterior chamber</p>
							<p class="table-body">More rapid vision rehabilitation</p>
							<p class="table-body">Less need for sutures</p>
							<p class="table-body">Minimal requirements for donor tissue</p>
							<p class="table-body">Reduced incidence of graft rejection</p>
						</td>
						<td class="Basic-Table CellOverride-23" />
						<td class="Basic-Table CellOverride-23">
							<p class="table-body">Selective removal of pathologic tissue</p>
							<p class="table-body">Reduced risk of penetration of anterior chamber</p>
							<p class="table-body">Preservation of globe integrity due to stronger wound than in PK</p>
							<p class="table-body">Minimal requirements for donor tissue</p>
							<p class="table-body">Early removal of sutures</p>
						</td>
						<td class="Basic-Table CellOverride-23" />
						<td class="Basic-Table CellOverride-23">
							<p class="table-body">Rapid vision rehabilitation</p>
							<p class="table-body">Preservation of ocular surface</p>
							<p class="table-body">Less induced astigmatism </p>
							<p class="table-body">Greater accuracy in selection of intraocular lens for triple procedures</p>
							<p class="table-body">Stronger wound</p>
							<p class="table-body">Reduction in suture-related problems</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-40">
						<td class="Basic-Table CellOverride-24">
							<p class="table-body">Advantages <span class="CharOverride-3">(cont&apos;d)</span></p>
						</td>
						<td class="Basic-Table CellOverride-24" />
						<td class="Basic-Table CellOverride-24" />
						<td class="Basic-Table CellOverride-24" />
						<td class="Basic-Table CellOverride-24">
							<p class="table-body">Less risk for patients who adhere poorly to treatment or rub their eyes</p>
						</td>
						<td class="Basic-Table CellOverride-24" />
						<td class="Basic-Table CellOverride-24">
							<p class="table-body">Less chance of graft rejection without donor endothelium, allowing more flexibility in dose and duration of postop steroid prophylaxis</p>
							<p class="table-body">Less risk for patients who adhere poorly to treatment or rub their eyes</p>
						</td>
						<td class="Basic-Table CellOverride-24" />
						<td class="Basic-Table CellOverride-24">
							<p class="table-body">Reduced incidence of graft rejection</p>
							<p class="table-body">Smaller incision with preservation of globe integrity</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-41">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Disadvantages</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Difficulty determining anterior corneal curvature, potentially leading to anisometropia</p>
							<p class="table-body">Ocular surface disease or neurotrophic cornea leads to prolonged healing or persistent epithelial defect</p>
							<p class="table-body">Irregular/significant regular astigmatism</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Irregular/significant regular corneal astigmatism</p>
							<p class="table-body">Irregular interface</p>
							<p class="table-body">Ocular surface disease or neurotrophic cornea leads to prolonged healing or persistent epithelial defect</p>
							<p class="table-body">Stromal opacification/interface debris</p>
							<p class="table-body">Procedure more technically demanding and time-consuming</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Irregular/significant regular corneal astigmatism</p>
							<p class="table-body">Irregular interface</p>
							<p class="table-body">Ocular surface disease or neurotrophic cornea leads to prolonged healing or persistent epithelial defect</p>
							<p class="table-body">Stromal opacification/interface debris </p>
							<p class="table-body">Procedure more technically demanding and time-consuming</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Significant stromal haze, subepithelial fibrosis, or epithelial irregularity may require second procedure</p>
							<p class="table-body">Reduction in BCVA in DSEK, less so in DMEK</p>
							<p class="table-body">Increased risk of primary graft failure during surgical learning curve </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-42">
						<td class="Basic-Table CellOverride-7" colspan="9">
							<p class="table-footnote">BCVA = best-corrected visual acuity; ICE = iridocorneal endothelial; IOP = intraocular pressure.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer027" class=" _idGenObjectLayout-2">
				<div id="_idContainer025" class="_idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer026" class="Basic-Text-Frame">
					<p class="table-cont-line">(Continued)</p>
				</div>
			</div>
		</div>
		<div id="_idContainer028" class="Basic-Text-Frame _idGenObjectStyleOverride-3">
			<p class="table-title"> <span class="CharOverride-3">(continued)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer031">
				<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-2813.png" alt="" />
				</div>
				<div id="_idContainer030" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-3</span> Slit-lamp photograph of primary donor failure after penetrating keratoplasty (PK).</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer034">
				<div id="_idContainer032" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9493.jpg" alt="" />
				</div>
				<div id="_idContainer033" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-4</span> Slit-lamp photograph showing recurrence of herpes simplex keratitis in a graft. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer037">
				<div id="_idContainer035" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6787.png" alt="" />
				</div>
				<div id="_idContainer036" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-5</span> Slit-lamp photograph showing recurrence of granular corneal dystrophy after cor-<br />neal transplantation. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer040">
				<div id="_idContainer038" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9494.png" alt="" />
				</div>
				<div id="_idContainer039" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-6</span> Slit-lamp photograph of an eroded continuous suture after PK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer043">
				<div id="_idContainer041" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9495.png" alt="" />
				</div>
				<div id="_idContainer042" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-7</span> Slit-lamp photograph of a suture abscess in a corneal graft. <span class="figure-source-note">(Courtesy of Stephen Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer046">
				<div id="_idContainer044" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9496.png" alt="" />
				</div>
				<div id="_idContainer045" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-8</span> Slit-lamp photograph showing infectious crystalline keratopathy after PK. <span class="figure-source-note">(Courtesy of Stephen Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer049">
				<div id="_idContainer047" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6790.png" alt="" />
				</div>
				<div id="_idContainer048" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-9</span> Slit-lamp photograph showing an epithelial rejection line <span class="figure-caption-italic">(arrow)</span> with subepithelial infiltrates <span class="figure-caption-italic">(arrowhead)</span> after PK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer052">
				<div id="_idContainer050" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6816.png" alt="" />
				</div>
				<div id="_idContainer051" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-10</span> Slit-lamp photograph showing corneal graft rejection manifested by subepithelial infiltrates. <span class="figure-source-note">(Courtesy of Charles&#160;S. Bouchard, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer055">
				<div id="_idContainer053" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9497.png" alt="" />
				</div>
				<div id="_idContainer054" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-11</span> Slit-lamp photograph showing corneal endothelial graft rejection with epithelial and stromal edema. Note the Khodadoust line <span class="figure-caption-italic">(arrows).</span> <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer058">
				<div id="_idContainer056" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6789.png" alt="" />
				</div>
				<div id="_idContainer057" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-12</span> Corneal topography with a Nidek OPD showing astigmatism after corneal transplantation. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer061">
				<div id="_idContainer059" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-2809.png" alt="" />
				</div>
				<div id="_idContainer060" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-13</span> <span class="figure-caption-bold">A,</span>&#160;Slit-lamp photograph of a descemetocele in a patient with rheumatoid arthritis. <span class="figure-caption-bold">B,</span>&#160;The same patient after lamellar keratoplasty.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer064">
				<div id="_idContainer062" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9498.png" alt="" />
				</div>
				<div id="_idContainer063" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-14</span> Stromal haze&#160;<span class="figure-caption-bold">(A)</span> and deep vascularization&#160;<span class="figure-caption-bold">(B)</span> following deep anterior lamellar keratoplasty. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer065" class="Basic-Text-Frame">
			<table id="table008" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-43" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-45" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="17">
							<p class="table-title"><span class="table-number">Table 15-7</span> Statistics for DSEK and DMEK Procedures Performed in the United States, 2013–2016</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">2016</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">%</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">2015</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">%</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">2014</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">%</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">2013</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head ParaOverride-25">%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Total EK procedures</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-27">28,327</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-27">27,208</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-27">25,965</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-27">24,987</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">DSAEK</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">21,868</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">77.0</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">22,514</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">83.0</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">23,100</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">89.0</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">23,465</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body ParaOverride-27">91.0</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">DMEK</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">6459</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">23.0</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">4694</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">17.0</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">2865</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">11.0</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">1522</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-27">9.3</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-21">
						<td class="Basic-Table CellOverride-7" colspan="17">
							<p class="table-source-note">Modified with permission from the Eye Bank Association of America (EBAA). <span class="CharOverride-3">2016 Eye Banking Statistical Report.</span> Washington, DC: EBAA; 2017.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer066" class="Basic-Text-Frame">
			<table id="table009" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-46" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-47" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-48" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-49" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-50" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="9">
							<p class="table-title"><span class="table-number">Table 15-8</span> Comparison of Short-Term Results for Different Surgical Techniques for Corneal Edema (Fuchs Dystrophy and PBK)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">PK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">DLEK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">DSAEK</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">DMEK</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Dislocation rate</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">0.0%</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">6.6%</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">14.5%</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">5.0%–62.0%<span class="CharOverride-6">*</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Wound dehiscence</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">1.3%–5.8%</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Donor failure within 60&#160;days</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">0.3%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">3.3%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">0%–29.0%; mean 5.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">2.2%–8.0%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Rejection rate at:</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">1 year</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">17.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">3.4%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">6.0%–9.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">0.7%–3.0%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">2 years</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">9.7%–13.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">5.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">12.0%–14.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">5 years</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">22.2%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">22.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Graft failure rate at 5&#160;years</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">5.0% for Fuchs/<br />27.0% for PBK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">27.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">5.0% for Fuchs/<br />24.0% for PBK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">BSCVA:</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-51">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">% 20/40 or better at 1 year</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">65.0%–84.0% with selective suture removal</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">40.0%–44.1%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">38.0%–90.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">94.0% at <br />6 months</p>
							<p class="table-body">97.0% 20/30 or better at <br />1 year</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">% 20/20 or better</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">39.0%–47.0%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Time to BCVA</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">6–12 months with selective suture removal</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="CharOverride-7">2</span>∕<span class="CharOverride-7">3</span> stable by 3&#160;months</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Mean keratometric cylinder:</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">Sutures out</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">4.40±2.80 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">1.50±1.20 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-52">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">at 2 years</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">3.70±3.20 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">0.40–0.60 D induced; mean <br />0.10 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">0.40–0.60 D induced; mean 0.10 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">+0.40 D hyperopic shift; no change</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">With sutures in at 1&#160;year</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">2.50 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Mean spherical equivalent change</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">2.80±2.10 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">0.90±0.70 D</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">+1.10 D induced hyperopia</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">+0.24 to <br />+0.32 D</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Endothelial cell loss at:</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">1 year</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">9.0%–19.0% Fuchs<span class="table-superscript">†</span></p>
							<p class="table-body">34.0% Fuchs/PBK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">43.0%–57.9%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">37.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">32.0±20.0%, 34.0%, 36.0%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-5">
							<p class="table-indent-1">2 years</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">27.0%–42.0% Fuchs,</p>
							<p class="table-body">54.0% Fuchs/PBK</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">57.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">44.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-53">
						<td class="Basic-Table CellOverride-6">
							<p class="table-indent-1">5 years</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">69.0%–75.0% Fuchs,</p>
							<p class="table-body">61.0% Fuchs/PBK</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">62.0% at 4&#160;years</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">53.0%</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-54">
						<td class="Basic-Table CellOverride-7" colspan="9">
							<p class="table-footnote ParaOverride-24">BSCVA = best spectacle-corrected visual acuity; BCVA = best-corrected visual acuity; D = diopter; DSAEK&#160;= Descemet stripping automated endothelial keratoplasty; NA = data not available; PBK = pseudophakic bullous keratopathy.</p>
							<p class="table-footnote"><span class="table-superscript-note-ast-">*</span>&#9;Includes only dislocations that influenced the result; edge dislocation or tag not counted. If all dislocations are counted, then 8.0%–24.0%.</p>
							<p class="table-footnote"><span class="table-superscript-notes">†</span><span class="table-superscript-notes">&#9;</span>Range: 2 donor age groups.</p>
							<p class="table-source-note">Modified from American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="table-source-emphasis">Corneal Edema and Opacification.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer069">
				<div id="_idContainer067" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-7764.png" alt="" />
				</div>
				<div id="_idContainer068" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-15</span> Iris prolapse following blunt trauma after Descemet stripping endothelial keratoplasty (DSEK). <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer072">
				<div id="_idContainer070" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9501.png" alt="" />
				</div>
				<div id="_idContainer071" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-16</span> <span class="figure-caption-bold">A,</span>&#160;Hemorrhage in the interface after DSEK. <span class="figure-caption-bold">B,</span>&#160;Slit-lamp photograph showing blood in the interface. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer075">
				<div id="_idContainer073" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-7765.png" alt="" />
				</div>
				<div id="_idContainer074" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-17</span> Residual air bubble following DSEK (postoperative day&#160;1). <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer078">
				<div id="_idContainer076" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9503.png" alt="" />
				</div>
				<div id="_idContainer077" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-18</span> Residual air bubble after Descemet membrane endothelial keratoplasty (DMEK) (postoperative day&#160;1). The S&#160;stamp is shown for orientation. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer081">
				<div id="_idContainer079" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-19</span> Slit-lamp photograph of a detached donor corneal button following DSEK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
				<div id="_idContainer080" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6814.png" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer084">
				<div id="_idContainer082" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9504.png" alt="" />
				</div>
				<div id="_idContainer083" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-20</span> Slit-lamp photograph of a peripheral detachment following DMEK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer087">
				<div id="_idContainer085" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9505.png" alt="" />
				</div>
				<div id="_idContainer086" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-21</span> Anterior segment optical coherence tomography images of a peripheral detachment following DMEK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer090">
				<div id="_idContainer088" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-7767.png" alt="" />
				</div>
				<div id="_idContainer089" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-22</span> Slit-lamp photograph showing pupillary block following DSEK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer093">
				<div id="_idContainer091" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9506.png" alt="" />
				</div>
				<div id="_idContainer092" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-23</span> <span class="figure-caption-bold">A,</span>&#160;Slit-lamp photograph of pupillary block following DMEK. <span class="figure-caption-bold">B,</span>&#160;The same patient after the release of air, leading to resolution of the block. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer096">
				<div id="_idContainer094" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6815.png" alt="" />
				</div>
				<div id="_idContainer095" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-24</span> Slit-lamp photograph of epithelial ingrowth <span class="figure-caption-italic">(arrow)</span> in the interface after DSEK. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer099">
				<div id="_idContainer097" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-25</span> Slit-lamp photograph of textural interface opacity after DSEK. <span class="figure-source-note">(Courtesy of Jeffrey Goshe, MD.)</span></p>
				</div>
				<div id="_idContainer098" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-9509.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer102">
				<div id="_idContainer100" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-7769.jpg" alt="" />
				</div>
				<div id="_idContainer101" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-26</span> Slit-lamp photograph showing endothelial graft rejection after DSEK, characterized by scattered keratic precipitates without an endothelial rejection line. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer105">
				<div id="_idContainer103" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 15-27</span> Boston keratoprosthesis type&#160;I. <span class="figure-source-note">(Courtesy of James&#160;J. Reidy, MD.)</span></p>
				</div>
				<div id="_idContainer104" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC2017-2018_S08_ch15_p411-454-web-resources/image/AAX-6792.jpg" alt="" />
				</div>
			</div>
		</div>
		<div id="_idContainer106" class="Basic-Text-Frame">
			<table id="table010" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-48" />
					<col class="_idGenTableRowColumn-55" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-56" />
					<col class="_idGenTableRowColumn-48" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="5">
							<p class="table-title"><span class="table-number">Table 15-9</span> Complications of Keratoprosthesis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Complication</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Incidence</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Glaucoma</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Preexisting in 72.0%–86.0%</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Retroprosthetic membrane formation</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">25.0%–55.0%</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Persistent epithelial defects</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">38.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Stromal necrosis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">16.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Endophthalmitis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">12.5%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Cystoid macular edema</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">8.7%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Infectious keratitis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">8.0%</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Extrusion of implant</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">0%–12.5%</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-7" colspan="5">
							<p class="table-source-note">Reproduced from American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="CharOverride-3">Corneal Edema and Opacification.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
	</body>
</html>
